The Intriguing Effects of Substituents in the N-Phenethyl Moiety of Norhydromorphone: A Bifunctional Opioid from a Set of “Tail Wags Dog” Experiments by Wang, Meining et al.
molecules
Article
The Intriguing Effects of Substituents in the
N-Phenethyl Moiety of Norhydromorphone:
A Bifunctional Opioid from a Set of “Tail Wags
Dog” Experiments
Meining Wang 1, Thomas C. Irvin 1, Christine A. Herdman 1, Ramsey D. Hanna 1,
Sergio A. Hassan 2 , Yong-Sok Lee 2 , Sophia Kaska 3, Rachel Saylor Crowley 3,
Thomas E. Prisinzano 3 , Sarah L. Withey 4, Carol A. Paronis 4 , Jack Bergman 4, Saadet Inan 5 ,
Ellen B. Geller 5, Martin W. Adler 5, Theresa A. Kopajtic 6, Jonathan L. Katz 6,
Aaron M. Chadderdon 7, John R. Traynor 7, Arthur E. Jacobson 1,* and Kenner C. Rice 1,*
1 Department of Health and Human Services, Drug Design and Synthesis Section, Molecular Targets and
Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and the
National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, 9800 Medical Center
Drive, Bethesda, MD 20892-3373, USA; wangmeining8911@163.com (M.W.); Tom.irvin8@gmail.com (T.C.I.);
caherdman@gmail.com (C.A.H.); Ramsey.hanna1@gmail.com (R.D.H.)
2 Department of Health and Human Services, Center for Molecular Modeling, Office of Intramural Research,
Center for Information Technology, National Institutes of Health, Bethesda, MD 20892, USA;
hassan@mail.nih.gov (S.A.H.); leeys@mail.nih.gov (Y.-S.L.)
3 Department of Medicinal Chemistry, School of Pharmacy, University of Kansas,
Lawrence, KS 66045-7582, USA; sophia.kaska@uky.edu (S.K.); crowleyrachels@gmail.com (R.S.C.);
prisinzano@uky.edu (T.E.P.)
4 Behavioral Biology Program, McLean Hospital/Harvard Medical School, 115 Mill Street,
Belmont, MA 02478, USA; swithey@mclean.harvard.edu (S.L.W.); cparonis@mclean.harvard.edu (C.A.P.);
jbergman@hms.harvard.edu (J.B.)
5 Center for Substance Abuse Research, Lewis Katz School of Medicine of Temple University,
3500 N. Broad St., Philadelphia, PA 19140, USA; sinan@temple.edu (S.I.); gellerellen@gmail.com (E.B.G.);
baldeagl@temple.edu (M.W.A.)
6 Department of Health and Human Services, Psychobiology Section, Molecular Neuropsychiatry Research
Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health,
Baltimore, MD 21224, USA; theresa.kopajtic@gmail.com (T.A.K.); jkatzzz@gmail.com (J.L.K.)
7 Department of Pharmacology and Edward F Domino Research Center, University of Michigan Medical
School, Ann Arbor, MI 48109, USA; Aaron.Chadderdon@gmail.com (A.M.C.); jtraynor@umich.edu (J.R.T.)
* Correspondence: arthurj@nida.nih.gov (A.E.J.); kennerr@nida.nih.gov (K.C.R.);
Tel.: +1-301-451-5028 (A.E.J.); +1-301-451-4799 (K.C.R.)
Academic Editor: Mariana Spetea
Received: 24 April 2020; Accepted: 3 June 2020; Published: 6 June 2020


Abstract: (−)-N-Phenethyl analogs of optically pure N-norhydromorphone were synthesized and
pharmacologically evaluated in several in vitro assays (opioid receptor binding, stimulation of
[35S]GTPγS binding, forskolin-induced cAMP accumulation assay, and MOR-mediated β-arrestin
recruitment assays). “Body” and “tail” interactions with opioid receptors (a subset of Portoghese’s
message-address theory) were used for molecular modeling and simulations, where the “address”
can be considered the “body” of the hydromorphone molecule and the “message” delivered by
the substituent (tail) on the aromatic ring of the N-phenethyl moiety. One compound, N-p-chloro-
phenethynorhydromorphone ((7aR,12bS)-3-(4-chlorophenethyl)-9-hydroxy-2,3,4,4a,5,6-hexahydro-
1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one, 2i), was found to have nanomolar binding
affinity at MOR and DOR. It was a potent partial agonist at MOR and a full potent agonist at DOR
with a δ/µ potency ratio of 1.2 in the ([35S]GTPγS) assay. Bifunctional opioids that interact with MOR
and DOR, the latter as agonists or antagonists, have been reported to have fewer side-effects than
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MOR agonists. The p-chlorophenethyl compound 2i was evaluated for its effect on respiration in both
mice and squirrel monkeys. Compound 2i did not depress respiration (using normal air) in mice
or squirrel monkeys. However, under conditions of hypercapnia (using air mixed with 5% CO2),
respiration was depressed in squirrel monkeys.
Keywords: opioid; bifunctional ligands; (−)-N-phenethylnorhydromorphone analogs; [35S]GTPgammaS
assay; forskolin-induced cAMP accumulation assays; β-arrestin recruitment assays; MOR and DOR
agonists; respiratory depression; bias factor; molecular modeling & simulation
1. Introduction
It is well-known that various N-substituents in the classical opioid-type of structure (e.g., 4,5-epoxy
morphinans, morphinans, 6,7-benzomorphans, 5-phenylmorphans) can change prototypical N-methyl
substituted agonist opioids to opioid antagonists. Most familiar, replacement of the N-methyl with
an N-allyl moiety in morphine and oxymorphone converted them to the antagonists nalorphine and
naloxone (Scheme 1).
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Exactly how the N-substituent interaction with amino acid residues in the receptor induces that 
change remains uncertain. The N-methyl substituent in morphine and oxymorphone either permits 
or does not prevent the ligand from receptor interactions that result in analgesia and the well-known 
panoply of opioid side-effects. Concurrent with their interaction with G-proteins, potent clinically 
utilized opioids also recruit β-arrestin2. This recruitment has been hypothesized to underly the 
undesirable effects of opioids, including respiratory depression, inhibited gastrointestinal transport, 
and tolerance [1–4], although recent data using β-arrestin2 knockout mice cast doubt on that 
hypothesis [4]. 
Replacement of an N-methyl group with a different substituent, the N-phenethyl moiety, has 
also been shown to change an opioid agonist to an antagonist in at least one of the types of classical 
opioids; however, that outcome is not consistent for all opioid structures. Most N-phenethyl-
substituted opioids, such as N-phenethylnormorphine [5], N-phenethylnoroxymorphone [6], and 2′-
hydroxy-5,9-dimethyl-N-phenethylbenzomorphan [6] have been found to be potent μ-opioid 
receptor (MOR) agonists, but N-phenethyl-5-phenylmorphan acts as a MOR antagonist [7]. In that 5-
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f an N-methyl group with a different substituent, the N-phenethyl moiety, has also
been shown to change opioid agonist t an ant gonist in at least on of the types of clas ical opioids;
however, that outcome is no nsistent for all opioid structures. Most N-phenethyl-substituted opioids,
ch as N-phenethylnormorphine [5], N-phenethylnoroxymor o [6], and 2′-hydroxy-5,9-dimethyl-
N-phenethylbenzomorphan [6] hav been found to be potent µ-opioid receptor (MOR) ag nists,
but N-phenethyl-5-phenylmorphan acts as a MOR antagonist [7]. In that 5-phenylmorpha series,
we found that the agonist vs antagonist activity of the compound was dependent on chirality.
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The 1R,5R,9S-enantiomer of the N-p-nitrophenethyl-5-phenylmorphan was found to be a potent MOR
agonist, and the 1S,5S,9R-enantiomer acted as a MOR antagonist [8].
N-Phenethylnorhydromorphone (S11, Scheme S1 in the Supplementary Material) was first
synthesized in 2001 by Lo and McErlane in 1.3% yield; it was not further examined at that time because
their synthesis did not provide the quantity of S11 necessary for in vitro or in vivo assays [9]. It could
be anticipated that it, like N-phenethylnormorphine and all other classical opioids, would display the
side-effects displayed by morphine. We obtained S11 through an improved synthesis (see Scheme S1 in
the Supplementary Material), and we found that S11 acts as a bifunctional ligand, with a DOR-MOR δ/µ
ratio = 39 in a functional assay (Table 2). It displayed extremely high MOR potency (EC50 = 0.04 nM)
compared to morphine (EC50 = 4.7 nM), DOR potency (EC50 = 1.54 nM), and also κ-opioid receptor
(KOR) activity (EC50 = 23 nM). This interesting pharmacology prompted our use of S11 as a template for
modifying its activity with the addition of different substituents on the nitrogen atom. We hypothesized
that relatively small changes in, for example, the N-phenethyl group, hereafter referred to as the
“tail” of the molecule, e.g., by adding substituents in various positions on the aromatic ring (Table 1),
might modify the ligand’s activity and, perhaps, enhance its therapeutic potential. This “tail wags
dog” experiment can be considered a subset of the message-address concept [10] as applied to opioids,
where the “address” can be considered the bulk of the hydromorphone molecule and the “message”
delivered by the substituent on the aromatic ring of the N-phenethyl moiety. We needed to modulate
(decrease) the agonist potency of the S11 compound at MOR and KOR without disturbing its DOR
activity. Since we were unaware of a theoretical model that could predict which substituent would
be able to tweak the molecule in that way, we decided to begin our exploration with the design and
synthesis and evaluation of compounds with varied substituents on the nitrogen atom and on the
aromatic ring of the phenethyl moiety, followed by rationalization of their activity using molecular
modeling and dynamics simulations.
A bifunctional compound that acted as a MOR agonist and DOR antagonist would be of the
greatest interest, since that combination of receptor interactions is believed to produce antinociceptive
activity with fewer of the unfortunate side-effects of opioids [11–13]. The receptor interaction induced
by ligands with MOR agonist and DOR agonist activity would also be of interest because that type of
combination of MOR and DOR occupancy has also been noted to produce fewer of the undesirable
side-effects caused by MOR agonist opioids [14–16]. For example, Su et al., have found that one of
the DOR functions was to modulate or counteract the respiratory depression caused by the MOR
and, most importantly, further noted that both DOR agonists and DOR antagonists acted similarly
in counteracting respiratory depression [17]. It has been found that deaths due to opioid overdose
are directly related to an opioid’s effect on respiratory depression [18]. It is theoretically possible that
a potent agonist with the “correct” δ/µ potency ratio would have diminished effects on respiration
or not depress respiration at all. The question of what that “correct” δ/µ ratio might be has not as
yet been answered. Our previous attempts to determine this in the 5-phenylmorphan series failed
due to their lack of potency [19,20]. There have been many reports of lessened side-effects induced
by bifunctional ligands, mostly reduced gastrointestinal effects, a few equivocal results on reduced
tolerance and dependence, and other reports have indicated reduced respiratory depression [21–27].
2. Results and Discussion
2.1. Chemistry
To prepare the necessary quantity of N-norhydromophone base (S10 in Scheme S1, see Supplementary
Material) we used a previously reported efficient process (hydromorphone synthesis, Scheme S1) for the
conversion of (−)-tetrahydrothebaine (S1) to dihydromorphine (S3) [28]. We found that using the HCl
salt of compound S3 as the reactant instead of the hydrate (product of the basic hydrolysis of S2) could
dramatically increase the yield of the oxidation [29], achieving hydromorphone hydrochloride (S4) in
90% yield. Transformation of hydromorphone S4 into one of our key intermediates, S7, was performed
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in four steps [30]. Optically pure (−)-N-substituted hydromorphone analogs with different substituents
on the N-phenethyl moiety were obtained by N-alkylation of the secondary amine S10 (Scheme 2).
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2.2. In Vitro Studies
We prepared four groups of compounds (Scheme 2); two cyano analogs (1a, 1b) and two aromatic
ring compounds without substituents (1c, 1d) in group 1, two N-nitrophenethyl compounds (2a, 2b) in
group 2, N-p-methylphenethyl and p-methoxyphenethyl compounds (2c, 2d) in group 3, and three
fluorophenethyl-substituted compounds (2e, 2f, 2g), a p-trifluoromethylphenethyl (2h), and a
p-chlorophenethyl (2i) compound in group 4. Opioid receptor binding data (Ki, nM) and stimulation of
([35S]GTPγS) binding were obtained for all of these compounds (Table 1). Two additional compounds
were added to group 4 in Table 2 (forskolin-induced cAMP accumulation assay), a 4-bromo (2j) and
a 2,6-dichlorophenethyl compound (2k), and two additional compounds were added to group 1,
hydromorphone (S5) and N-phenethylnorhydromorphone (S11). These four compounds were only
examined using the forskolin-induced cAMP accumulation assay. The ability of all of the compounds
to recruit β-arrestin was also determined (Table 2).
Opioid receptor binding data (Ki, nM) and stimulation of ([35S]GTPγS) binding were obtained
for all of these compounds (Table 1). Two additional compounds were added to group 4 in Table 2
(forskolin-induced cAMP accumulation assay), a 4-bromo (2j) and a 2,6-dichlorophenethyl compound (2k),
and two additional compounds were added to group 1, hydromorphone (S5) and N-phenethylnor
hydromorphone (S11). These four compounds were only examined using the forskolin-induced cAMP
accumulation assay. The ability of all of the compounds to recruit β-arrestin was also determined
(Table 2).
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Table 1. Opioid Receptor Binding Data a (Ki, nM) and Stimulation of [35S]GTPγS b Binding at MOR (µ), DOR (δ) and KOR (κ) opioid receptors.
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2.4 ± 0.3  
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0.32 ± 0.04 3.57 ± 0.49 23.2 ± 2.8 
2.1 ± 0.7 
(100 ± 0.3)  
92.7 ± 17.0 
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DNS 
0.87 ± 0.10 13.4 ± 0.9 44.3 ± 6.0 2.5 ± 0.3(42.6 ± 2.9)
64.2 ± 9.9
(243 ± 49) DNS
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0.49 ± 0.07 4.48 ± 0.43 30.2 ± 2.3 
2.4 ± 0.3  
(56.8 ± 7.5)  
54.1 ± 4.7  




0.32 ± 0.04 3.57 ± 0.49 23.2 ± 2.8 
2.1 ± 0.7 
(100 ± 0.3)  
92.7 ± 17.0 
(83.0 ± 3.3) 
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5.88 ± 0.38 92.5 ± 7.3 65.4 ± 7.7 DNS NT NT 
Group 3. Alkyl and Alkoxy Substituents 
2c 
 
0.86 ± 0.12 6.34 ± 0.65 44.0 ± 3.8 
1.9 ± 0.7 
(55.6 ± 2.1)  
23.1 ± 6.9 
(95.4 ± 3.8)  
38.1 ± 10.6 
(31.4 ± 4.2)  
2d 
 
0.67 ± 0.05 5.43 ± 0.47 26.3 ± 1.9 DNS 
33.6 ± 6.4 
(48.9 ± 3.2) 
5.9 ± 1.7 
(21.8 ± 0.8) 
Group 4. Halides and Trifluromethyl Substituents 
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0.87 ± 0.10 13.4 ± 0.9 44.3 ± 6.0 
2.5 ± 0.3  
(42.6 ± 2.9)  
64.2 ± 9.9  




0.49 ± 0.07 4.48 ± 0.43 30.2 ± 2.3 
2.4 ± 0.3  
(56.8 ± 7.5)  
54.1 ± 4.7  




0.32 ± 0.04 3.57 ± 0.49 23.2 ± 2.8 
2.1 ± 0.7 
(100 ± 0.3)  
92.7 ± 17.0 
(83.0 ± 3.3) 




(83.0 ± 3.3) DNS
2h
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2h 
 
2.70 ± 0.17 16.4 ± 0.4 NT 
3.4 ± 1.2 
(72.2 ± 5.5) 
35.7 ± 12.3 




1.09 ± 0.06 7.89 ± 1.10 NT 
2.0 ± 1.0 
(39.0 ± 2.1) 
2.4 ± 0.7 
(83.8 ± 3.7) 
NT 
Standard 
- Morphine 3.26 ± 0.39 NT 145 ± 15 
194 ± 21 
(57 ± 5) [31]  
NT NT 
a Binding assays were typically conducted in at least three independent experiments, each performed with triplicate observations using whole rat brains excluding 
cerebellum; Ki± SEM (nM); NT = not tested—inactive (<50% activity at 100 nM concentration in exploratory binding assays (displaced less than half of radioligand). 
Also, compounds with low binding affinity (>50 nM) were not further examined in functional assays); b [35S]GTPγS functional assays: % stimulation compared to 
standard maximal at each receptor MOR = DAMGO; DOR = DPDPE; KOR = U69593) in C6 cells expressing MOR or DOR or CHO cells expressing KOR. All 
experiments were repeated on three separate occasions in duplicate. Values are given as means ± SEM; DNS = no stimulation (indicates antagonist activity when 
coupled with high receptor binding affinity); c EC50 = Effective dose for 50% maximal response. 
2.70 ± 0.17 16.4 ± 0.4 NT 3.4 ± 1.2(72.2 ± 5.5)
35.7 ± 12.3
(82.3 ± 2.3) NT
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2.70 ± 0.17 16.4 ± 0.4 T 
3.4 ± 1.2 
(72.2 ± 5.5) 
35.7 ± 12.3 




1.09 ± 0.06 7.89 ± 1.10 T 
2.0 ± 1.0 
(39.0 ± 2.1) 
2.4 ± 0.7 
(83.8 ± 3.7) 
T 
Standard 
- orphine 3.26 ± 0.39 T 145 ± 15 
194 ± 21 
(57 ± 5) [31]  
T T 
a Binding assays ere typically conducted in at least three independent experi ents, each perfor ed ith triplicate observations using hole rat brains excluding 
cerebellu ; i± SE  (n ); T = not tested inactive (<50  activity at 100 n  concentration in exploratory binding assays (displaced less than half of radioligand). 
lso, co pounds ith lo  binding affinity (>50 n ) ere not further exa ined in functional assays); b [35S] TPγS functional assays:  sti ulation co pared to 
standard axi al at each receptor  = ;  = P PE;  = 69593) in 6 cells expressing  or  or  cells expressing . ll 
experi ents ere repeated on three separate occasions in duplicate. alues are given as eans ± SE ; S = no sti ulation (indicates antagonist activity hen 
coupled ith high receptor binding affinity); c E 50 = Effective dose for 50  axi al response. 
1.09 ± 0.06 7.89 ± 1.10 NT 2.0 ± 1.0(39.0 ± 2.1)
2.4 ± 0.7
(83.8 ± 3.7) NT
Standard
- Morphine 3.26 ± 0.39 NT 145 ± 15 194 ± 21(57 ± 5) [31] NT NT
a Binding assays were typically conducted in at least three independent experiments, each performed with triplicate observations using whole rat brains excluding cerebellum; Ki ± SEM (nM);
NT = not tested—inactive (<50% activity at 100 M concen ration in xploratory binding assays (dis laced less than alf of radioligand). Also, compounds with low bi ding affinity
(>50 nM) were not further examined in functional assays); b [35S]GTPγS functional assays: % stimulation compared to standard maximal at each receptor MOR = DAMGO; DOR = DPDPE;
KOR = U69593) in C6 cells expressing MOR or DOR or CHO cells expressing KOR. All experiments were repeated on three separate occasions in duplicate. Values are given as means ± SEM;
DNS = no stim lation ( ndicates a tagonist act vity whe coupl d with high r ceptor b ding affinity); c EC50 = Effective dose for 50% maxim response.
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Table 2. Opioid Receptor Activity Measured in the Forskolin-induced cAMP Accumulation Assay a.
Compound Structure
MOR cAMP Agonist







Potency ± SEM (nM)
(% Efficacy)
KOR cAMP Agonist
Potency ± SEM (nM)
(% Efficacy)
Group 1. N-Cyanoalkyl Compounds and Compounds Lacking Substituents on the Aromatic Ring
1a
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596 ± 92
(94.4 ± 1.4) >10,000
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Hydromorphone
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(73.97 ± 5.49) 
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- DAMGO 
0.3 ± 0.04 
(101.5 ± 0.5) 
44.1 ± 3.9 
(103 ± 0.4) 
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Potency ± SEM (nM)
(% Efficacy)
KOR cAMP Agonist
Potency ± SEM (nM)
(% Efficacy)
Standards
- DAMGO 0.3 ± 0.04(101.5 ± 0.5)
44.1 ± 3.9
(103 ± 0.4) 1.0 -
- U-69593 - - - - 0.7 ± 0.3(101.2 ± 1.4)
- Leu-Enkephalin - - - 0.04 ± 0.10(95 ± 2) -
- Morphine 4.7 ± 0.6(102.9 ± 0.6)
378 ± 41
(25.7 ± 0.6) 2.27 - -
a Inhibition of forskolin-induced cAMP accumulation; DAMGO (([D-Ala2, N-MePhe4, Gly-ol]-enkephalin); U-69593 ((+)-(5α,7α,8β)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-
benzeneacetamide); Leu-Enkephalin (Tyr-Gly-Gly-Phe-Leu). To determine % efficacy of MOR-mediated β-arrestin recruitment, the highest dose(s) of DAMGO were used as 100% and the
respective data were converted to percentages based on the response of DAMGO and analyzed using GraphPad Prism. To determine % efficacy in forskolin-induced cAMP assays,
data were normalized to the vehicle control, followed by the forskolin control. Data were then analyzed in GraphPad Prism using nonlinear regression.
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2.2.1. Opioid Receptor Binding, Ligand Efficacy and Potency ([35S]GTPγS Binding Assays)
The MOR binding affinity, in the receptor binding assay, of N-cyanomethyl (1a) and N-cyanopropyl
compounds (1b) in group 1 (Table 1), both without an aromatic ring on the nitrogen atom,
were comparable to the affinity of morphine (Ki = 4.51 and 4.25 vs 3.26 for morphine). However, 1a had
only partial MOR agonist activity (47% stimulation) and very low potency (EC50 = 425 nM) in the
[35S]GTPγS assay (Table 1), and 1b, in contrast, was a MOR antagonist in that assay (antagonist activity
was assumed given the high MOR binding affinity, and lack of [35S]GTPγS stimulation at MOR). All of
the compounds in group 1 (Table 1) that were assessed at DOR had relatively low receptor binding
affinity (Ki > 70 nM). At KOR, 1a had a Ki of about 90 nM, whereas 1b had a higher binding affinity at
KOR than MOR, a > 30-fold increase in KOR agonist affinity due to the extension of the carbon chain
from N-cyanomethyl to N-cyanopropyl. Compounds in group 1 with an extended and rotationally
restricted N-substituent (compound 1c) or a bulky N-substituent (compound 1d) showed little binding
affinity or potency at any opioid receptor. Compounds were considered inactive and were not tested
(NT) in functional assays when they were found to displace <50% of the radioligand at a 100 nM
concentration in an exploratory binding assay (not described in the Material and Methods Section).
The m-(2b) and p-N-nitrophenethylnorhydromorphone (2a) in group 2 in Table 1 showed a
>10-fold difference in MOR binding affinity in the receptor binding assay and a remarkable change
from potent MOR agonist 2a to MOR antagonist 2b (Table 1) was observed in the [35S]GTPγS assay,
apparently induced by the change in the position of the aromatic ring’s substituent. This bolstered our
hypothesis that we could influence and considerably alter activity by substitution on the phenyl ring.
The group 3 alkyl and alkoxy compounds had very high MOR affinity (Ki < 1 nM) and high
DOR affinity (Ki = 5–6 nM) in the receptor binding assay, and while 2c was a potent partial MOR
agonist in the [35S]GTPγS assay, the methoxy compound 2d appeared to be a MOR antagonist in
that assay. Both of these compounds had EC50 < 35 nM at DOR with 2c acting as a full agonist
(95% stimulation) and 2d a partial agonist (49% stimulation). Compound 2d was also a potent KOR
agonist (EC50 = 5.9 nM), although it was not efficacious at KOR (21.8% stimulation).
The halides in group 4 (Table 1) harbored the most interesting compound 2i, from the perspective
of having a desirable δ/µ potency ratio. All of the halides had high affinity at MOR and DOR (Ki ranged
from 0.3 to 2.7 nM at MOR and 4 to 16 nM at DOR), and less affinity at KOR (Ki > 20 nM), in the
receptor binding assays. Additionally, all group 4 compounds had nanomolar MOR potency in the
[35S]GTPγS assay (EC50 = 2.0–3.4 nM) and all except 2i and 2h had lower DOR agonist potency
(EC50 > 50 nM). The trifluoromethyl compound 2h had moderate DOR potency (EC50 = 36 nM),
whereas 2i had nanomolar potency at DOR (EC50 = 2.4 nM), with a δ/µ potency ratio of 1.2.
2.2.2. Ligand Potency and Efficacy Using the Forskolin-induced cAMP Accumulation Assay
As seen in the forskolin-induced cAMP accumulation assay (group 1, Table 2), 1a had morphine-like
potency, as it did in the [35S]GTPγS assay. In contrast, compounds 1a, 1c and 1d had relatively low
potency for DOR or KOR cAMP stimulation.
Again, as in the [35S]GTPγS assay, 1c with restricted rotation and 1d with a bulky side-chain were
less potent than the cyanomethyl compound 1a. The standard compounds for comparison purposes,
S5 and S11, hydromophone and N-phenethylnorhydromorphone in group 1, were relatively potent
at MOR (EC50 = 1.67 and 0.04 nM, respectively) and S11 was potent at DOR (EC50 = 1.54 nM) and
somewhat less potent at KOR (EC50 = 22.7 nM). The parent compound hydromorphone (S5) was
essentially inactive at DOR and KOR (EC50 > 130 nM). The N-phenethylnorhydromorphone (S11),
had an EC50 δ/µ ratio = 38.5, and that was possibly too high for the mitigation of side-effects that might
be provided by interaction with DOR.
The bias factor of all of the tested compounds ranged between ca. 0.4 and 3.5 (Table 2). Examination
of the MOR β-arrestin recruitment for S11 and 2i indicated that they both had a lower bias factor than
morphine (indicating their greater ability to recruit β-arrestin). All of these G-protein biased ligands
recruit β-arrestin almost as well, or better than morphine. If recruitment of β-arrestin correlated with
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the side-effects of these compounds, they should all cause, for example, respiratory depression, as well
as other side-effects caused by interaction with MOR. As noted previously, however, the ability of
MOR ligands to recruit β-arrestin may not have any bearing on whether they will or will not display
opioid-like side-effects [4].
The MOR antagonist profile of 2a in group 2 (Table 1), the p-nitro compound, that was seen in
the [35S]GTPγS assay was not observed in the forskolin-induced cAMP accumulation assay (Table 2).
In the cAMP assay, both 2a and 2b had MOR agonist activity (EC50 = 0.05 and 5.2 nM, respectively);
a >100-fold potency change due to a positional shift of an aromatic substituent.
In group 3 in Table 2, the alkyl and alkoxy compounds, 2c and 2d, were found to have relatively
high potency (EC50 = 0.08 and 0.13 nM, respectively) at MOR and at DOR (EC50 = 1.0 and 2.7 nM,
respectively. They were also KOR agonists (EC50 = 8.7 and 7.4 nM, respectively). In the cAMP assay
(Table 2), 2d was not found to have MOR antagonist activity.
In group 4 (Table 2), the most interesting compound was again found to be 2i. It had extremely
high agonist potency at MOR and DOR (EC50 = 0.05 and 0.53 nM, respectively), and was efficacious at
both receptors. It was much less potent at KOR (EC50 = 55 nM). The o-fluoro compound 2g was notable
for its relatively high MOR agonist potency (0.01 nM), with full (101%) efficacy. The p-bromo compound
2j also appeared to be of interest in that its EC50 δ/µ ratio = 6.5 was less than the ratio found for 2i in the
cAMP assay (δ/µ ratio = 10 for 2i). Compound 2j was also potent at both MOR and DOR in the cAMP
assay (EC50 < 1 nM), but it had moderate agonist potency at KOR (20 nM). Although KOR agonists
have therapeutic potential, they also have undesirable CNS-mediated side-effects (e.g., dysphoria,
hallucinations) [32].
We hypothesized that a compound with a δ/µ potency ratio of less than 7 in the [35S]GTPγS assay
would be desirable if the compound were to display other than the full array of undesirable effects that
clinically used analgesics manifest. Recent work on bifunctional compounds explored compounds
with δ/µ potency ratios of 5 to 7 in [35S]GTPγS assay assays, and found that those compounds had a
less disruptive effect on locomotor activity than morphine or oxymorphone [33].
2.2.3. Molecular Modeling and Simulations.
Specifically placed moieties at the tail end of the N-phenethyl substituent changed the compound
from a MOR partial agonist in the [35S]GTPγS assay (e.g., N-p-nitrophenethyl-norhydromorphone,
2a) to a MOR antagonist (e.g., N-m-nitrophenethylnorhydromorphone, 2b). In the forskolin-induced
cAMP accumulation assay, that same positional shift of the substituent in the aromatic ring in 2a to 2b
caused a >100 fold change in potency. We used quantum chemical calculations and molecular dynamics
simulations to determine if a moiety in precise positions on the aromatic ring in the N-phenethyl
moiety of norhydromorphone would display sufficient differences in their interaction with MOR to
induce the change in activity and/or potency. More generally, our simulations allowed us to identify
the critical residues interacting with the body (Figure 1) and the tail (Figure 2) of the ligands that are
responsible for the differences in receptor properties. Together, the experimental and simulation data
led us to propose a set of general rules for the N-phenethyl-substitutions to impart specific behaviors,
such as partial or full agonist or possible antagonist activities, which may help design compound with
novel properties (see details in the Supplementary Materials).
Body-Opioid Receptor (OR) interactions
All the compounds considered in our simulations have similar body-OR interaction patterns
regardless of the substituents on the N-phenethyl ring; the interactions are consistent with those
reported recently for a series of phenethyl oxymorphone compound bound to the active MOR [33].
These are shown in Figure 1 for both the MOR and the DOR, and involve polar/charged residues
in transmembrane helix (TMH) 3, 5 and 6, and hydrophobic residues in TMH 5, 6, and 7. A contact
is deemed significant if it persists for at least 50% of the time (see example in Table S2), although
not necessarily all the interactions are seen at a given time. Different substituents, however, lead to
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different statistics of the individual interactions due to modest repositioning of the ligands resulting
from different tail-OR interactions. All the residues in direct contact with the body are conserved in
both receptors. Three additional, non-conserved residues, each belonging to TMH 5, 6, and 7 interact
indirectly with -O- and -OH groups of the body via short water chains. Thus, suitable substitutions
that engage these residues more directly (e.g., polar or H-bond interactions) may help modulate the
MOR and DOR activity, potency and affinities independently.
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Figure 1. Conserved polar/charged residues (in red; numbering as in MOR) that interacted with the -O
and -OH groups of the N-phenethylnorhydromorphone body through H-bonds; the body was also
stabilized by close packing with four conserved nonpolar residues (blue) through hydrophobic forces.
Although not in direct interactions, a few non-conserved residues (green) were seen to interact with the
ligands indirectly through short water chains. These residues may thus be important to modulate the
behavior of MOR and DOR independently, which may be accomplished through specific substituents
that can engage them more directly. Frequencies of contacts were deemed statistically relevant if
they were observed at least 25% of the time, except for the critical -NH—D147 distance (MOR) and
-NH—D128 distance (DOR) that was required to persist for at least 75% of the time for the confor er to
be considered (see details of the analysis in Table S2).
Tail-OR interactions
Because the tail is located deep inside the pocket, relatively s all changes in the N-phenylethyl
ring via substitutions perturb residues located in different regions of the Rs and engage different
T s (Figure S1). The constrained environ ent of the tail suggests that these interactions can induce
ajor changes in the R structure and/or dyna ics, as confir ed by preli inary data fro principal
co ponent analysis (to be published). nlike the relatively rigid ligand body, the tail has several
energetically similar conformers (Figure S2). Some of these conformers can be ruled out based on
unfavorable steric interactions (cf. Computational Section 5). However, the simulations show that
all of the conformers selected by the pocket can be stabilized because each substituent can always
find favorable interactions through polar/nonpolar or H-bond interactions. It is noted that none of
these conformers lose the critical polar/H-bond interaction between the protonated nitrogen of the
ligands and the carboxylate of the anchoring aspartic acid D147 (MOR) or D128 (DOR) (cf. Table S2).
The multiplicity of binding modes may explain, in part, the tendency of most ligands in the Table 1
series to display partial agonist activity, i.e., with some modes leading to agonist and others to
antagonist activity. This scenario may coexist with the more traditional view of partial activity as
the result of multiple substates of the receptor stabilized by a single conformer (not observed in the
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simulations). We carried out a comparative analysis of the experimental observations summarized
in Table S1. Here we focused on the results pertaining to the effects of F and Cl substitution at the
p-position of the N-phenethyl moiety on both receptors (Figure 2A, additional details in SI). The p-F
(2e) was found to be a potent partial MOR agonist and weak partial DOR agonist, whereas p-Cl (2i),
although still a potent partial MOR agonist, becomes a potent full DOR agonist, an unexpected result
with therapeutic potential.
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shown (see text); (B) p-Cl (potent partial MOR agonists); the two conf rmers shown. The red li es
represent frequent, statistically significant interactions that were obtained from the dynamic simulations.
Sequence numbering as in the corresponding ORs.
One of the conformers of 2e and of 2i showed the same pattern of interactions with the DOR,
engaging both TMH 6 (W274) and 7 (N310, S311, N314); this conformer (not shown) was expected to
elicit the same dynamic behavior of the receptor and was unlikely to be responsible for the observed
partial vs. full agonist activities. The second conformer did show qualitative differences (Figure S2A);
when compared to 2e, 2i partially disengaged TMH 7 and engaged TMH 3. On the one hand, Cl is
larger than F, resulting in higher polarizability together with a longer C-Cl bond distance, and is less
electronegative, resulting in a less negative partial charge and weaker electric field at the atom surface.
These differences appeared to be enough for 2i to interact more favorably with both S135 and S311,
which were in opposite sides across the pocket; 2e instead interacted more closely with the polar
groups of adjacent N310 and N314 on the same TMH 7. In both cases, the ligands interacted with TMH
6, showing persistent interactions with the -NH group of W274 and with the H atoms on the F270
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ring via weak polar interactions. Although halogen-bonding interactions were not included in the
forcefield [34,35], it could be predicted that the incipient σ-hole and equatorial negative charge of the
Cl atom (Figure S2) would further stabilize this pattern of interactions. There may be other qualitative
differences between 2e and 2i if the latter interacts with the aromatic ring via C-Cl/π interactions [36];
in this case, the side-chain may adopt a different conformation and affect the dynamics of TMH 6.
Despite the differences in the pattern of interactions, the type and frequency of polar and non-polar
contacts were fundamentally the same in both ligands, which may explain their similar Ki values.
When all the interactions were considered, only two residues of DOR show unique interactions with
these ligands: N314 (only with 2e) and S135 (only with 2i). Therefore, substituents that interacted with
S135 (or engaged TMH 3 near this residue) and interacted less strongly with N314 (or disengaged
TMH 7) may confer potent full DOR agonism. The difference in atomic size, polarizability, and
electronegativity, as well as the putative C-Cl/π interactions, appear to play a role in the difference
between 2e and 2i. Accordingly, it would be of interest to see the effects of p-Br and p-I on DOR
behavior. In MOR, the patterns of interactions of 2i were similar to those in DOR (Figure 2B): one
conformer interacted with TMH 6 and 7 and the other with TMH 3 and 7. This may be enough to impart
potent agonism, as in the DOR, but only partial agonist activity in MOR. When all the interactions
were considered, F289 is the only residue that was unique in the interaction patterns of 2i with the
receptors. The present investigation indicated that changing the balance of interactions of the phenethyl
ring with S154, N332, and F289 by a suitable substituent may help design potent, full DOR agonists.
The constrained environment of the tail substituent on the aromatic ring of the N-phenethyl
moiety located deep inside the receptor pocket suggested that these interactions can induce major
changes in the OR structure or dynamics. The consequences of such effects were already observed in
a previous study where a p-NO2 substitution in the ring elicited significant changes in OR activity
and efficacy [8]; computational studies of other GPCRs have also shown the importance of the lower
strata of the binding pocket to affect function [37]. Thus, moieties in specific positions on the phenyl
ring in N-phenethylnorhydromorphone might convert a potent MOR agonist to MOR antagonist or
significantly change its potency. This was shown using in vitro assays with the nitro substituent on the
phenyl ring (in 2a and 2b, Table 1). Depending on the position of the nitro substituent in the phenyl
ring, one of the compounds (with a p-nitro substituent, 2a) was a potent low efficacy MOR agonist
with subnanomolar affinity and the other (with a m-nitro substituent, 2b) was a high-affinity MOR
antagonist in the [35S]GTPγS assay (Table 1), a minor positional change inducing a significant change
in activity. In the forskolin-induced cAMP accumulation assay, a major difference in potency was
observed with these compounds.
2.3. In Vivo Data
2.3.1. Respiratory Depression Assays in Mice
The p-chlorophenyl compound 2i was among the most interesting of the compounds in that it
exhibited high MOR and DOR affinity and potency and was a potent efficacious DOR agonist and a
partial MOR agonist in the [35S]GTPγS assay (Table 1). It was an exceptionally potent MOR agonist in
the forskolin-induced cAMP accumulation assay (Table 2). Few compounds have been noted in the
literature that combine potent MOR partial agonist and potent DOR full agonist activity in a δ/µ ratio
of about 7 in opioid receptor binding studies and in a δ/µ ratio of about 1 from potency studies in the
[35S]GTPγS assay (Table 1). We thought that it would be of interest to further examine that compound
in vivo.
In mice, 2i did not depress respiration rate in the presence of normal air. Figure 3A shows time
courses of saline, morphine (10 mg/kg), and different doses of 2i on respiration rate. Figure 3B shows
the calculated area under the curve (AUCs) from 6 min to 45 min post injection. As seen in Figure 3B,
10 mg/kg morphine significantly reduced (p < 0.0001) respiration rate compared to saline (One-way
ANOVA revealed a significant effect for treatment F(5,38) = 18.34, p < 0.0001).
Molecules 2020, 25, 2640 17 of 32
Molecules 2020, 25, x 17 of 33 
 
ratio of about 7 in opioid receptor binding studies and in a δ/μ ratio of about 1 from potency studies 
in the [35S]GTPγS assay (Table 1). We thought that it would be of interest to further examine that 
compound in vivo. 
In mice, 2i did not depress respiration rate in the presence of normal air. Figure 3A shows time 
courses of saline, morphine (10 mg/kg), and different doses of 2i on respiration rate. Figure 3B shows 
the calculated area under the curve (AUCs) from 6 min to 45 min post injection. As seen in Figure 3B, 
10 mg/kg morphine significantly reduced (p < 0.0001) respiration rate compared to saline (One-way 




Figure 3. Effects of morphine and 2i on respiratory rate in mice. After acclimation in observation 
boxes, mice were injected with either saline, morphine 10 mg/kg, or 2i and connected to a throat 
sensor. Five min later, the recording was started and respiratory rate was measured from 6 min to 45 
min post-injection (A). Area under the curve (AUC) was calculated from 6 min to 45 min. Morphine 
significantly reduced respiratory rate compared to saline (B). Data are expressed as mean ± standard 
error of the mean (SEM.) (n = 6–8) (**** p <0.0001). One-way ANOVA followed by Dunnett’s multiple 
comparison test. 
The doses chosen were based on the squirrel monkey tail withdrawal latency assay and the 
highest dose (0.1 mg/kg) was about 5 or 6 times higher than the ED50 values at 50 and 52 °C from the 
tail withdrawal latency assay (the usual dose studied to observe side-effects is about 4× the ED50). 
Compound 2i (0.01–0.1 mg/kg) had no effect on respiration rate in this assay in mice although 
Figure 3. Effects of morphine and 2i on respiratory rate in mice. After ac limation in observation
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The doses chosen were based on the squirrel monkey tail withdrawal latency assay and the
highest dose (0.1 mg/kg) was about 5 or 6 times higher than the ED50 values at 50 and 52 ◦C from
the tail withdrawal latency assay (the usual dose studied to observe side-effects is about 4× the
ED50). Compound 2i (0.01–0.1 mg/kg) had no effect on respiration rate in this assay in mice although
morphine, as expected, significantly decreased respiratory rate. Results for oxygen saturation (SpO2)
indicated that neither morphine nor 2i had any effect on SpO2. from 6 min to 45 min post-injection
(data not shown).
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2.3.2. Antinociceptive Studies and Respiratory Depression Studies in Squirrel Monkeys
Further studies evaluated the effects of 2i and, for comparison, morphine, in assays of antinociception
and respiratory depression in nonhuman primates. In a squirrel monkey tail withdrawal latency assay,
the p-chlorophenethyl compound 2i exhibited the observed partial MOR agonist in vitro characteristics
(in the [35S]GTPγS assay) by having a full effect at moderate (50 ◦C) and hot (52 ◦C) but not at very
hot (55 ◦C) water temperatures. In comparison, morphine elicited full antinociceptive effects at all
three water temperatures. The compound 2i, like morphine, also produced dose-related behavioral
impairment, evident as decreases in operant performance and, consequently, the number of reinforcers
obtained during an operant task interspersed between tail-withdrawal tests. The doses of 2i that
produced behavioral impairment were similar to those that produce antinociception in 50 ◦C and 52 ◦C
water (Figure 4).
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Figure 4. Effects of 2i on tail withdrawal latency from different temperatures of water (filled symbols)
and operant behavior disruption (open symbols) in squirrel monkeys (n = 4). Data are expressed as
mean ± SEM (n = 4).
The ED50 doses for producing antinociception at 50 ◦C or 52 ◦C were, respectively, 0.010 and
0.015 mg/kg, an the ED50 dose for reducing the number of reinforcers earned (b havioral impairme t),
was 0.022 m /kg, resulting in ED50 rati s (b havioral impair ent/antinociception) that were about 2 or
less. Ratio values greater than 1 imply some behavioral selectivity in observed effects although, as can
be s en in Table 3, morphine had an ven greater behavi ral imp irment/antinocicepti n potency ratio
than did 2i. Further studie evaluated wh ther 2i differed from morphin in its cap city to produce
res iratory depression in squirrel monkeys.
The results from a respiratory depression ass y in squirrel monkeys correlated somewhat with data
obtained using mice. As shown in Figure 5 during exposure to air alone, neither 2i (0.003–0.1 mg/kg)
nor morphine (0.03–3.0 mg/kg) had effects on respiratory rate or overall ventilation (minute volume)
in squirrel monkeys, whereas in mice morphine (10 mg/kg), but not 2i (0.01–0.1 mg/kg), depressed
ventilation. In contrast, during exposure to 5% CO2 mixed in air (hypercapnia), both 2i and morphine
significantly decreased ventilation in squirrel monkeys, resulting from respiratory depressant effects
(Figure 5).
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Table 3. ED50 values and ratios of ED50 values for effects measured in squirrel monkeys.
Behavioral Measures 2i Morphine
ED50 (mg/kg)
Antinociception (52 ◦C) a 0.015 0.14
Behavioral Disruption b 0.022 1.30
Respiratory Depression c 0.057 1.06
Potency Ratios
Behavioral Disruption: Antinociception 1.5 9.0
Respiratory Depression: Antinociception 3.9 7.3
Respiratory Depression: Behavioral Disruption 2.6 0.8
a Dose required to increase tail withdrawal latency to 5 s; b dose required to reduce the number of reinforcements
earned to 5 per cycle; c dose required to decrease minute volume in 5% CO2 to 50% of the baseline value.
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Figure 5. Effects in squirrel monkeys of 2i and morphine on respiratory rate (bottom panels) or on
minute volume (top panels) in the presence of nor al air (open symbols) or air mixed with 5% CO2
(filled symbols). 2i and morphine significantly reduced minute volume in 5% CO2 without significantly
altering respiratory rate. Data are expressed as mean ± SEM. (n = 4); (*) indicates the difference from
saline (p ≤ 0.01; one-way ANOVA followed by Dunnett’s multiple comparison test.
The ED50 values for producing antinociception in 52 ◦C water, decreasing the number of reinforcers
earned in an oper nt behavio al task, and decreasing ve tilation in 5% CO2, as well as calculated
pote cy ratios cross the pr cedures, are summarized in Table 3. Here, a complicated picture emerges
in which morphi e has a larger, and hence more f vorable, potency ratio for antinociceptive and
behaviorally disruptive effect than does 2i, whereas 2i has a higher ratio for behaviorally disruptive
and respiratory depressant effects. Indeed, the potency ratio for morphine for behavioral disruption
and respiratory depression was ≤ 1, indicating that breathing was decreased at similar doses to those
that decreased behavior, whereas 2-fold higher doses of 2i were needed to decrease CO2-stimulated
breathing (Figure 5).
The ED50 values for producing antinociception in 52 ◦C water, decreasing the number of reinforcers
earned in an operant behavioral task, and decreasing ventilation in 5% CO2, as well as calculated potency
ratios across the procedures, are summarized in Table 3. Here, a complicated picture emerges in which
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morphine has a larger, and hence more favorable, potency ratio for antinociceptive and behaviorally
disruptive effect than does 2i, whereas 2i has a higher ratio for behaviorally disruptive and respiratory
depressant effects. Indeed, the potency ratio for morphine for behavioral disruption and respiratory
depression was ≤1, indicating that breathing was decreased at similar doses to those that decreased
behavior, whereas 2-fold higher doses of 2i were needed to decrease CO2-stimulated breathing.
3. Material and Methods
3.1. General Information
Melting points were determined on a B-545 instrument (Büchi, Labortechnik AG, Flawii,
Switzerland) and are uncorrected. Proton and carbon nuclear magnetic resonance (1H and 13C-NMR)
spectra were recorded on a Gemini-400 spectrometer (Varian, Palo Alto, CA, USA) with the values given
in ppm (TMS as internal standard) and J (Hz) assignments of 1H resonance coupling. Mass spectra
(HRMS) were recorded on a VG 7070E spectrometer (VG Analytical Ltd., Altrincham, Cheshire,
England, UK) or a SX102a mass spectrometer (JEOL, Tokyo, Japan) 41 polarimeter (PerkinElmer,
Shelton, CT, USA) at room temperature. Gas chromatography (GC) was performed on a 6850 GC
system (Agilent Technologies, Santa Clara, CA, USA) equipped with a VL MSD detector. Thin layer
chromatography (TLC) analyses were carried out on prepackaged plates using various gradients of
CHCl3/MeOH containing 1% of 28% NH4OH (CMA) or gradients of EtOAc:n-hexane. Visualization
was accomplished under UV light or by staining in an iodine chamber. Flash column chromatography
was performed using RediSep Rf normal phase silica gel cartridges. Atlantic Microlabs, Inc. (Norcross,
GA, USA) or Micro-Analysis, Inc. (Wilmington, DE, USA) performed elemental analyses, and the
results were within ± 0.4% of the theoretical values. All spectra were obtained on the free base.
3.2. Synthesis. General Procedure for Formation of Tertiary Amines.
(7aR,12bS)-3-(4-Chlorophenethyl)-9-hydroxy-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]-
isoquinolin-7(7aH)-one (2i): To a stirred solution of N-norhydromorphone (S10 in the Supplementary
Materials, 0.406 g, 1.5 mmol) in DMF (10 mL) were added NaHCO3 (0.504 g, 6 mmol) and
1-(2-bromoethyl)-4-chlorobenzene (0.480 mL, 3.3 mmol). The mixture was heated at 90 ◦C overnight,
cooled to room temperature, filtered through Celite, and concentrated in vacuo. Water (10 mL) was
added and the mixture extracted with CHCl3 (3 × 20 mL). The combined organics were washed with
H2O (5 × 20 mL), dried over Na2SO4, filtered through Celite, and concentrated in vacuo to afford
2i free base as a crude colorless oil. Purification of this oil by SiO2 column chromatography with
10% NH4OH in MeOH/CHCl3 (gradient, 0 → 4% of 10% NH4OH) afforded 2i (0.420 g, 70%) as a
colorless oil. 1H-NMR (DMSO-d6): δ 9.09 (s, 1H), 7.30 (d, J = 8.4 Hz, 2H), 7.26 (d, J = 8.4 Hz, 2H), 6.51
(d, J = 8.0 Hz, 1H), 6.46 (d, J = 7.6 Hz, 1H), 4.78 (s, 1H), 3.17 (s, 1H), 2.79 (d, J = 18.4 Hz, 1H), 2.71–2.56
(m, 5H), 2.52 (dd, J = 14.4 Hz, 4.8 Hz, 1H), 2.48–2.40 (m, 1H), 2.23 (dd, J = 18.2 Hz, 5.4 Hz, 1H), 2.11
(d, J = 13.6 Hz, 1H), 2.04–1.93 (m, 2H), 1.76–1.71 (m, 1H), 1.47 (d, J = 10.0 Hz, 1H), 1.01–0.91 (m, 1H);
13C-NMR (DMSO-d6): δ 209.2, 144.3, 140.1, 139.6, 131.0, 130.8, 128.5, 127.9, 124.9, 119.6, 117.3, 90.7, 57.3,
56.4, 47.1, 44.8, 41.8, 40.1, 35.3, 33.4, 25.5, 21.2; HRMS (TOF MS ES+) calcd for C24H25ClNO3 (M + H+)
410.1523, found 410.1527. 2i HCl: An HCl salt was prepared by dissolving 2i free base in hot i-PrOH
(5.0 mL) followed by the addition of 37% HCl (0.10 mL, 3 equiv). It was concentrated in vacuo to afford
the salt. Anal. Calcd for C24H24ClNO3.0.5H2O·0.5C3H8O (2i HCl·0.5H2O·0.5C3H8O): C, 63.29; H, 6.11;
N, 2.77; found: C, 63.09; H, 6.23; N, 2.89%. [α]20D − 138.5 (c 0.65, MeOH, HCl·0.5H2O·0.5i-PrOH).
2-((7aR,12bS)-9-Hydroxy-7-oxo-1,2,4,4a,5,6,7,7a-octahydro-3H-4,12-methanobenzofuro[3,2-e]isoquinolin-
3-yl)acetonitrile (1a): The general procedure with S10 (0.406 g, 1.5 mmol), 2-bromoacetonitrile (0.230 mL,
3.3 mmol), NaHCO3 (0.504 g, 6 mmol), and DMF (10 mL) at room temperature. Purification by column
chromatography afforded 1a free base (0.250 g, 50%) as a white solid. 1H-NMR (CD3OD): δ 6.61 (d,
J = 8.0 Hz, 1H), 6.56 (d, J = 8.4 Hz, 1H), 4.76 (s, 1H), 3.74 (d, J = 17.2 Hz, 1H), 3.63 (d, J = 17.2 Hz, 1H),
3.36 (dd, J = 5.2 Hz, 2.8 Hz, 1H), 2.99 (d, J = 18.4 Hz, 1H), 2.69 (dd, J = 11.6 Hz, 3.6 Hz, 1H), 2.62 (dt,
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J = 12.6 Hz, 3.4 Hz, 1H), 2.53 (td, J = 14.0 Hz, 4.4 Hz, 1H), 2.46-2.35 (m, 2H), 2.28 (dt, J = 14.0 Hz, 3.0 Hz,
1H), 2.13 (td, J = 12.4 Hz, 4.8 Hz, 1H), 1.89–1.83 (m, 1H), 1.72 (ddd, J = 12.4 Hz, 3.2 Hz, 1.6 Hz, 1H),
1.14 (ddd, J = 27.2 Hz, 13.2 Hz, 2.8 Hz, 1H); 13C-NMR (CD3OD): δ 210.0, 144.1, 139.4, 126.7, 124.4,
119.7, 117.4, 117.0, 90.9, 58.3, 46.7, 44.4, 42.2, 41.8, 39.2, 34.5, 25.1, 21.1; HRMS (TOF MS ES+) calcd for
C18H19N2O3 [M + H]+ 311.1396, found 311.1397. Anal. Calcd for C18H18N2O3·0.1CHCl3·0.25H2O
(1a·0.1CHCl3·0.25H2O): C, 66.48; H, 5.42; N, 8.46; found: C, 66.52; H, 5.74; N, 8.57%. [α]20D −190.5
(c 0.43, CHCl3/MeOH (20/1)).
2-((7aR,12bS)-9-Hydroxy-7-oxo-1,2,4,4a,5,6,7,7a-octahydro-3H-4,12-methanobenzofuro[3,2-e]isoquinolin-
3-yl)butanenitrile (1b): The general procedure with S10 (0.406 g, 1.5 mmol), 4-bromobutanenitrile
(0.344 mL, 3.3 mmol), NaHCO3 (0.504 g, 6 mmol), and DMF (10 mL). Purification by column
chromatography afforded 1b free base (0.350 g, 70%) as a colorless oil. 1H-NMR (CD3OD): δ 6.59
(d, J = 8.0 Hz, 1H), 6.54 (d, J = 8.4 Hz, 1H), 4.74 (s, 1H), 3.22 (dd, J = 5.6 Hz, 2.8 Hz, 1H), 2.91 (d,
J = 18.4 Hz, 1H), 2.72–2.48 (m, 7H), 2.37 (dd, J = 18.4 Hz, 5.6 Hz, 1H), 2.28 (dt, J = 13.6 Hz, 3.2 Hz,
1H), 2.19 (td, J = 12.0 Hz, 3.2 Hz, 1H), 2.09 (td, J = 12.0 Hz, 4.4 Hz, 1H), 1.88–1.77 (m, 3H), 1.66 (ddd,
J = 12.4 Hz, 3.0 Hz, 1.8 Hz, 1H), 1.14 (ddd, J = 27.4 Hz, 13.0 Hz, 2.8 Hz, 1H); 13C-NMR (CD3OD) δ 210.4,
144.1, 139.1, 127.1, 125.0, 119.9, 119.6, 117.3, 91.0, 57.7, 52.8, 47.3, 44.5, 41.7, 39.4, 34.8, 25.3, 22.9, 20.8,
13.8; HRMS (TOF MS ES+) calcd for C20H23N2O3 [M + H]+ 339.1709, found 339.1711. An HCl salt was
prepared by dissolving 1b free base in hot i-PrOH (5.0 mL) followed by the addition of concentrated
aq HCl (0.10 mL, 3 equiv) and cooling to 5 ◦C. The crystals were filtered and air-dried to give 1b as
its HCl salt. Anal. Calcd for C20H22N2O3·HCl·1.5H2O·0.25C3H8O (1b·HCl·1.5H2O·0.25C3H8O): C,
59.65; H, 6.74; N, 6.49; found: C, 59.78; H, 6.77; N, 6.72%. [α]20D − 188.3 (c 0.6, CHCl3/MeOH (1/10),
HCl·1.5H2O·0.25C3H8O salt).
(7aR,12bS)-3-Cinnamyl-9-hydroxy-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-
7(7aH)-one (1c) Thkye general procedure with S10 (0.406 g, 1.5 mmol), (E)-(3-bromoprop-1-en-1-yl)
benzene (0.650 mg, 3.3 mmol), NaHCO3 (0.504 g, 6 mmol), and DMF (10 mL). Purification by column
chromatography and crystallization from MeOH afforded 1c free base (0.180 g, 31%) as a white solid.
1H-NMR (DMSO-d6) δ. 9.10 (s, 1H), 7.41 (d, J = 7.6 Hz, 2H), 7.29 (t, J = 7.4 Hz, 2H), 7.20 (t, J = 7.4 Hz,
1H), 6.57–6.49 (m, 3H), 6.26 (dt, J = 15.6 Hz, 6.4 Hz, 1H), 4.80 (s, 1H), 3.32–3.28 (m, 1H), 3.21–3.14 (m,
2H), 2.86 (d, J = 18.4 Hz, 1H), 2.57–2.48 (m, 3H), 2.23 (dd, J = 18.2 Hz, 5.4 Hz, 1H), 2.12 (dt, J = 14.0 Hz,
2.8 Hz, 1H), 2.01 (d, J = 7.2 Hz, 2H), 1.77–1.72 (m, 1H), 1.48 (d, J = 9.2 Hz, 1H), 0.97 (ddd, J = 27.2 Hz,
12.8 Hz, 2.2 Hz, 1H); 13C-NMR (DMSO-d6): δ 209.2, 144.4, 139.7, 137.2, 131.8, 129.0, 128.5, 127.9, 127.8,
126.6, 124.9, 119.6, 117.3, 90.8, 57.2, 56.9, 47.1, 45.0, 41.9, 40.1, 35.3, 25.5, 20.9; HRMS (TOF MS ES+) calcd
for C25H26NO3 [M + H]+ 388.1913, found 388.1906. Anal. Calcd for C25H25NO3·0.25H2O (1c·0.25H2O):
C, 76.60; H, 6.56; N, 3.57; found: C, 76.28; H, 6.42; N, 3.62%. [α]20D − 214.0 (c 0.4, CHCl3/MeOH (1/10)).
(7aR,12bS)-3-((2,3-Dihydro-1H-inden-2-yl)methyl)-9-hydroxy-2,3,4,4a,5,6-hexahydro-1H-4,12-methano-
benzofuro[3,2-e]isoquinolin-7(7aH)-one (1d): The general procedure with S10 (0.406 g, 1.5 mmol),
2-(bromomethyl)-2,3-dihydro-1H-indene (0.470 mL, 3.3 mmol), NaHCO3 (0.504 g, 6 mmol), and DMF
(10 mL). Purification column chromatography and crystallization from chloroform afforded 1d (0.190 g,
32%) as white solid. 1H-NMR (CD3OD): δ 7.16–7.14 (m, 2H), 7.08–7.05 (m, 2H), 6.60 (d, J = 8.0 Hz,
1H), 6.55 (d, J = 8.0 Hz, 1H), 4.75 (s, 1H), 3.24 (dd, J = 5.0 Hz, 2.6 Hz, 1H), 3.07–2.99 (m, 2H), 2.93 (d,
J = 18.4 Hz, 1H), 2.76–2.59 (m, 5H), 2.56–2.49 (m, 3H), 2.35–2.26 (m, 2H), 2.20 (td, J = 12.0 Hz, 3.0 Hz,
1H), 2.11 (td, J = 12.0 Hz, 4.2 Hz, 1H), 1.86–1.80 (m, 1H), 1.65 (d, J = 12.0 Hz, 1H), 1.13 (ddd, J = 27.2 Hz,
13.2 Hz, 2.2 Hz, 1H); 13C-NMR (CD3OD): δ 210.6, 144.1, 142.7, 142.6, 139.1, 127.2, 125.7, 125.2, 124.1,
119.6, 117.2, 91.1, 59.6, 57.5, 45.1, 41.8, 39.5, 37.2, 37.1, 37.0, 34.9, 25.4, 20.7; HRMS (TOF MS ES+) calcd
for C26H28NO3 [M + H]+ 402.2069, found 402.2068. Anal. Calcd for C26H27NO3·CHCl3 (1d·CHCl3): C,
62.30; H, 5.12; N, 2.68; found: C, 62.26; H, 5.42; N, 2.69%. [α]20D −137.0 (c 0.77, CHCl3/MeOH (10/1)).
(7aR,12bS)-9-Hydroxy-3-(4-nitrophenethyl)-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]-
isoquinolin-7(7aH)-one (2a): The general procedure with S10 (0.406 g, 1.5 mmol), 1-(2-bromoethyl)-4-
nitrobenzene (759 mg, 3.3 mmol), NaHCO3 (0.504 g, 6 mmol), and DMF (10 mL). Purification by
column chromatography afforded 2a (0.070 g, 10%) as a colorless oil. 1H-NMR (CD3OD): δ 8.16 (d,
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J = 8.4 Hz, 2H), 7.51 (d, J = 8.4 Hz, 2H), 6.61 (d, J = 8.4 Hz, 1H), 6.56 (d, J = 8.0 Hz, 1H), 4.77 (s, 1H),
3.32–3.30 (m, 1H), 2.99–2.72 (m, 6H), 2.61–2.49 (m, 2H), 2.38 (dd, J = 18.6 Hz, 5.8 Hz, 1H), 2.29 (dt,
J = 14.0 Hz, 3.0 Hz, 1H), 2.24 (td, J = 12.2 Hz, 3.4 Hz, 1H), 2.11 (td, J = 12.4 Hz, 4.8 Hz, 1H), 1.88–1.81
(m, 1H), 1.69 (d, J = 12.0 Hz, 1H), 1.15 (ddd, J = 27.2 Hz, 13.2 Hz, 2.0 Hz, 1H); 13C-NMR (100 MHz,
CD3OD): δ 210.4, 148.6, 146.5, 144.1, 139.2, 129.5, 127.0, 124.9, 123.0, 119.6, 117.3, 91.0, 57.5, 55.6, 47.2,
44.7, 41.6, 39.4, 34.7, 33.4, 25.3, 20.6; HRMS (TOF MS ES+) calcd for C24H25N2O5 [M + H]+ 421.1763,
found 421.1762. An HCl salt was prepared by dissolving 2a free base in hot i-PrOH (5.0 mL) followed
by the addition of concentrated aqueous HCl (0.10 mL, 3 equiv) and cooling to 5 ◦C. The crystals
were filtered and air-dried to give 2a as its HCl salt. Anal. Calcd for C24H24N2O5·HCl·1.75H2O
(2a·HCl·1.75H2O): C, 58.99; H, 5.69; N, 5.56; found: C, 59.02; H, 5.88; N, 5.74%. [α]20D −107 (c 0.4, MeOH,
HCl·1.75H2O salt).
(7aR,12bS)-9-Hydroxy-3-(3-nitrophenethyl)-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]-
0isoquinolin-7(7aH)-one (2b): The general procedure with S10 (0.406 g, 1.5 mmol), 1-(2-bromoethyl)-3-
nitrobenzene (759 mg, 3.3 mmol), NaHCO3 (0.504 g, 6 mmol), and DMF (10 mL). Purification by
column chromatography afforded 2b free base (0.035 g, 5%) as a colorless oil. 1H-NMR (CD3OD):
δ 8.16 (t, J = 3.0 Hz, 1H), 8.05 (ddd, J = 8.0 Hz, 2.4 Hz, 0.8 Hz, 1H), 7.66 (d, J = 7.6 Hz, 1H), 7.51 (t,
J = 7.8 Hz, 1H), 6.59 (d, J = 8.0 Hz, 1H), 6.55 (d, J = 8.0 Hz, 1H), 4.75 (s, 1H), 3.28–3.27 (m, 1H), 2.97–2.84
(m, 4H), 2.82–2.71 (m, 2H), 2.60–2.47 (m, 2H), 2.37 (dd, J = 18.6 Hz, 5.8 Hz, 1H), 2.30–2.21(m, 2H), 2.09
(td, J = 12.2 Hz, 4.6 Hz, 1H), 1.86–1.79 (m, 1H), 1.68 (ddd, J = 12.4 Hz, 3.2 Hz, 1.6 Hz, 1H), 1.13 (ddd,
J = 27.4 Hz, 13.0 Hz, 2.8 Hz, 1H); 13C-NMR (CD3OD): δ 210.3, 148.2, 144.1, 142.8, 139.2, 134.9, 129.0,
127.0, 125.0, 123.2, 120.6, 119.6, 117.3, 91.0, 57.5, 55.7, 47.3, 44.7, 41.7, 39.4, 34.8, 33.1, 25.3, 20.7; HRMS
(TOF MS ES+) calcd for C24H25N2O5 [M + H]+ 421.1763, found 421.1762. An HCl salt was prepared by
dissolving 2b free base in hot i-PrOH (5.0 mL) followed by the addition of concentrated aqueous HCl
(0.10 mL, 3 equiv) and cooling to 5 ◦C. The crystals were filtered and air-dried to give 2b as its HCl salt.
Anal. Calcd for C24H24N2O5·HCl·1.5H2O (2b·HCl·1.5H2O): C, 59.64; H, 5.55; N, 5.49; found: C, 59.56;
H, 5.83; N, 5.79%. [α]20D −137.9 (c 0.6, CHCl3/MeOH (1/20), HCl·1.5H2O).
(7aR,12bS)-9-Hydroxy-3-(4-methylphenethyl)-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]-
isoquinolin-7(7aH)-one (2c): The general procedure with S10 (0.406 g, 1.5 mmol), 1-(2-bromoethyl)-4-
methylbenzene (0.502 mL, 3.3 mmol), NaHCO3 (0.504 g, 6 mmol), and DMF (10 mL). Purification by
SiO2 column chromatography afforded 2c free base (0.330 g, 65%) as a colorless oil. 1H-NMR (CD3OD):
δ 7.11 (d, J = 8.4 Hz, 2H), 7.08 (d, J = 8.4 Hz, 2H), 6.61 (d, J = 8.4 Hz, 1H), 6.56 (d, J = 8.4 Hz, 1H),
4.77 (s, 1H), 3.36 (dd, J = 5.2 Hz, 2.4 Hz, 1H), 2.97 (d, J = 18.4 Hz, 1H), 2.80–2.65 (m, 5H), 2.62 (dt,
J = 12.8 Hz, 3.2 Hz, 1H), 2.53 (td, J = 14.0 Hz, 4.8 Hz, 1H), 2.36 (dd, J = 18.4 Hz, 5.6 Hz, 1H), 2.29 (dt,
J = 13.2 Hz, 3.0 Hz, 1H), 2.28 (s, 3H), 2.21 (td, J = 12.0 Hz, 2.1 Hz, 1H), 2.12 (td, J = 12.0 Hz, 4.0 Hz, 1H),
1.88–1.82 (m, 1H), 1.68 (d, J = 12.4 Hz, 1H), 1.15 (ddd, J = 27.0 Hz, 13.4 Hz, 2.4 Hz, 1H); 13C-NMR
(CD3OD): δ 210.3, 144.1, 139.2, 136.9, 135.2, 128.6, 128.2, 127.0, 124.8, 119.6, 117.3, 91.0, 57.0, 56.7,
47.2, 45.1, 41.4, 39.4, 34.6, 33.2, 25.4, 20.2, 19.7; HRMS (TOF MS ES+) calcd for C25H28NO3 [M + H]+
390.2069, found 390.2071. An HCl salt was prepared by dissolving 2c free base in hot MeOH (5.0 mL)
followed by the addition of concentrated aq HCl (0.10 mL, 3 equiv) and cooling to 5 ◦C. The crystals
were filtered and air-dried to give 2c as its HCl salt. Anal. Calcd for C25H27NO3·HCl·1.5H2O·0.5CH4O
(2c·HCl·1.5H2O·0.5CH4O): C, 65.56; H, 6.78; N, 2.92; found: C, 65.37; H, 7.09; N, 2.99%. [α]20D − 139.5
(c 0.63, MeOH, HCl·1.5H2O·0.5CH4O).
(7aR,12bS)-9-Hydroxy-3-(4-methoxyphenethyl)-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]-
isoquinolin-7(7aH)-one (2d): The general procedure with S10 (0.406 g, 1.5 mmol), 1-(2-bromoethyl)-4-
methoxybenzene (0.520 mL, 3.3 mmol), NaHCO3 (0.504 g, 6 mmol), and DMF (10 mL). Column
chromatography afforded 2d free base (0.370 g, 64%) as a colorless oil. 1H-NMR (DMSO-d6): δ 9.09 (s,
1H), 7.13 (d, J = 8.4 Hz, 2H), 6.81 (d, J = 8.4 Hz, 2H), 6.51 (d, J = 8.0 Hz, 1H), 6.46 (d, J = 8.4 Hz, 1H),
4.79 (s, 1H), 3.69 (s, 3H), 3.20 (s, 1H), 2.80 (d, J = 18.4 Hz, 1H), 2.63–2.53 (m, 5H), 2.51–2.44 (m, 2H),
2.23 (dd, J = 18.4 Hz, 5.6 Hz, 1H), 2.12 (d, J = 13.6 Hz, 1H), 2.01–1.97 (m, 2H), 1.76–1.72 (m, 1H), 1.47
(d, J = 9.2 Hz, 1H), 1.02–0.91 (m, 1H); 13C-NMR (DMSO-d6): δ 209.3, 157.9, 144.3, 139.6, 132.8, 130.0,
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128.0, 124.9, 119.6, 117.3, 114.0, 90.8, 57.2, 57.1, 55.4, 47.1, 44.9, 41.8, 40.1, 35.3, 33.4, 25.5, 21.0; HRMS
(TOF MS ES+) calcd for C25H28NO4 [M + H]+ 406.2018, found 406.2014. An HCl salt was prepared by
dissolving 2d free base in hot i-PrOH (5.0 mL) followed by the addition of concentrated aqueous HCl
(0.10 mL, 3 equiv) and cooling to 5 ◦C. The crystals were filtered and air-dried to give 2d as its HCl salt.
Anal. Calcd for C25H27NO4·HCl·0.5H2O·0.5C3H8O (2d·HCl·0.5H2O·0.5C3H8O): C, 66.19; H, 6.83; N,
2.77; found: C, 66.17; H, 6.92; N, 2.91%. [α]20D −136.5 (c 0.68, MeOH, HCl·0.5H2O·0.5i-PrOH).
(7aR,12bS)-9-Hydroxy-3-(4-fluorophenethyl)-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]-
isoquinolin-7(7aH)-one (2e): The general procedure with S10 (0.406 g, 1.5 mmol), 1-(2-bromoethyl)-4-
fluorobenzene (0.460 mL, 3.3 mmol), NaHCO3 (0.504 g, 6 mmol), and DMF (10 mL). Purification by
column chromatography afforded 2e free base (0.290 g, 50%) as a colorless oil. 1H-NMR (CD3OD): δ
7.24 (dd, J = 8.2 Hz, 5.4 Hz, 2H), 6.99 (t, J = 8.8 Hz, 2H), 6.60 (d, J = 8.0 Hz, 1H), 6.56 (d, J = 8.4 Hz,
1H), 4.77 (s, 1H), 3.30 (s, 1H), 2.97 (d, J = 18.4 Hz, 1H), 2.83–2.66 (m, 5H), 2.61 (dt, J = 12.8 Hz, 3.4 Hz,
1H), 2.52 (td, J = 14.2 Hz, 4.6 Hz, 1H), 2.37 (dd, J = 18.6 Hz, 5.8 Hz, 1H), 2.29 (dt, J = 14.0 Hz, 2.8 Hz,
1H), 2.22 (td, J = 12.0 Hz, 3.0 Hz, 1H), 2.12 (td, J = 12.0 Hz, 4.4 Hz, 1H), 1.88–1.82 (m, 1H), 1.69 (d,
J = 12.4 Hz, 1H), 1.15 (ddd, J = 27.2 Hz, 13.2 Hz, 2.4 Hz, 1H); 13C-NMR (CD3OD): δ 210.3, 162.7, 160.2,
144.1, 139.2, 136.0(2), 130.0(2), 127.0, 124.9, 119.6, 117.3, 114.6, 114.4, 91.0, 57.2, 56.6, 47.2, 45.0, 41.5, 39.4,
34.7, 32.8, 25.4, 20.4; HRMS (TOF MS ES+) calcd for C24H25FNO3 (M + H+) 394.1818, found 394.1825.
An HCl salt was prepared by dissolving 2e free base in hot i-PrOH (5.0 mL) followed by the addition
of concentrated aq HCl (0.10 mL, 3 equiv) and cooling to 5 ◦C. The crystals were filtered and air-dried
to give 2e as its HCl salt. Anal. Calcd for C24H24FNO3·HCl·1.5H2O (2e·HCl·1.5H2O): C, 63.14; H, 6.03;
N, 2.98; found: C, 63.09; H, 6.18; N, 3.07%. [α]20D − 137.8 (c 0.65, MeOH, HCl·1.5H2O).
(7aR,12bS)-9-Hydroxy-3-(3-fluorophenethyl)-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]-
isoquinolin-7(7aH)-one (2f): The general procedure with 10 (0.406 g, 1.5 mmol), 1-(2-bromoethyl)-3-
fluorobenzene (0.460 mL, 3.3 mmol), NaHCO3 (0.504 g, 6 mmol), and DMF (10 mL). Purification by
column chromatography afforded 2f free base (0.270 g, 46%) as colorless oil. 1H-NMR (CD3OD): δ 7.27
(dd, J = 14.0 Hz, 8.0 Hz, 1H), 7.05 (d, J = 7.6 Hz, 1H), 6.99 (d, J = 10.4 Hz, 1H), 6.90 (td, J = 8.6 Hz,
2.4 Hz, 1H), 6.61 (d, J = 8.4 Hz, 1H), 6.56 (d, J = 8.0 Hz, 1H), 4.76 (s, 1H), 3.34–3.32 (m, 1H), 2.96 (d,
J = 18.4 Hz, 1H), 2.85–2.68 (m, 5H), 2.60 (dt, J = 12.6 Hz, 3.4 Hz, 1H), 2.52 (td, J = 14.0 Hz, 4.6 Hz, 1H),
2.36 (dd, J = 18.4 Hz, 5.6 Hz, 1H), 2.28 (dt, J = 13.8 Hz, 2.1 Hz, 1H), 2.21 (td, J = 12.4 Hz, 3.2 Hz, 1H),
2.11 (td, J = 12.2 Hz, 4.4 Hz, 1H), 1.87–1.81 (m, 1H), 1.67 (d, J = 12.4 Hz, 1H), 1.14 (ddd, J = 26.8 Hz,
13.4 Hz, 2.4 Hz, 1H); 13C-NMR (CD3OD): δ 210.4, 164.1, 161.7, 144.1, 143.1, 143.0, 139.2, 129.7, 129.6,
127.0, 124.9, 124.3, 124.2, 119.7, 117.4, 115.1, 114.9, 112.5, 112.2, 91.0, 57.2, 56.1, 47.2, 44.9, 41.5, 39.4,
34.7, 33.3, 25.3, 20.4; HRMS (TOF MS ES+) calcd for C24H25FNO3 [M + H]+ 394.1818, found 394.1821.
An HCl salt was prepared by dissolving 2f free base in hot i-PrOH (5.0 mL) followed by the addition
of concentrated aqueous HCl (0.10 mL, 3 equiv) and cooling to 5 ◦C. The crystals were filtered and
air-dried to give 2f as its HCl salt. Anal. Calcd for C24H24FNO3·HCl·1.25H2O (2f·HCl·1.25H2O): C,
63.71; H, 6.13; N, 3.10; found: C, 63.71; H, 6.11; N, 3.11%. [α]20D −149.2 (c 0.48, MeOH, HCl·1.25H2O).
(7aR,12bS)-9-Hydroxy-3-(2-fluorophenethyl)-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]-
isoquinolin-7(7aH)-one (2g): The general procedure with S10 (0.406 g, 1.5 mmol), 1-(2-bromoethyl)-2-
fluorobenzene (0.460 mL, 3.3 mmol), NaHCO3 (0.504 g, 6 mmol), and DMF (10 mL). Purification by
column chromatography afforded 2g free base (0.260 g, 45%) as a colorless oil. 1H-NMR (CD3OD):
δ 7.31–7.27 (m, 1H), 7.24–7.19 (m, 1H), 7.11–7.01 (m, 2H), 6.61 (d, J = 8.4 Hz, 1H), 6.56 (d, J = 8.0 Hz,
1H), 4.77 (s, 1H), 3.36 (dd, J = 5.2 Hz, 2.8 Hz, 1H), 2.96 (d, J = 18.4 Hz, 1H), 2.94–2.66 (m, 5H), 2.61
(dt, J = 12.8 Hz, 3.4 Hz, 1H), 2.40 (td, J = 14.0 Hz, 4.6 Hz, 1H), 2.38 (dd, J = 18.6 Hz, 5.8 Hz, 1H),
2.29 (dt, J = 14.0 Hz, 3.0 Hz, 1H), 2.23 (td, J = 12.4 Hz, 3.2 Hz, 1H), 2.12 (td, J = 12.2 Hz, 4.6 Hz, 1H),
1.89–1.82 (m, 1H), 1.70–1.67 (m, 1H), 1.15 (ddd, J = 27.2 Hz, 13.4 Hz, 2.4 Hz, 1H); 13C-NMR (CD3OD):
δ 210.4, 162.4, 160.0, 144.0, 139.2, 130.9, 130.8, 127.8, 127.7, 127.0, 126.8, 126.6, 124.9, 123.9(2), 119.6,
117.3, 114.7, 114.5, 91.0, 57.2, 55.0, 47.2, 45.0, 41.5, 39.4, 34.7, 26.9(2), 25.4, 20.4; HRMS (TOF MS ES+)
calcd for C24H25FNO3 [M + H]+ 394.1818, found 394.1822. An HCl salt was prepared by dissolving 2g
free base in hot i-PrOH (5.0 mL) followed by the addition of concentrated aq HCl (0.10 mL, 3 equiv)
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and cooling to 5 ◦C. The crystals were filtered and air-dried to give 2g as its HCl salt. Anal. Calcd
for C24H24FNO3·HCl·1.5H2O (2g·HCl·1.5H2O): C, 63.51; H, 5.74; N, 3.05; found: C, 63.09; H, 6.18; N,
3.07%. [α]20D −135.7 (c 1.25, MeOH, HCl·1.5H2O).
(7aR,12bS)-9-Hydroxy-3-(4-(trifluoromethyl)phenethyl)-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzo
furo-[3,2-e]isoquinolin-7(7aH)-one (2h): The general procedure with S10 (0.406 g, 1.5 mmol), 1-(2-bromoethyl)-
4-(trifluoromethyl)benzene (0.554 mL, 3.3 mmol), NaHCO3 (0.504 g, 6 mmol), and DMF (10 mL).
Purification by column chromatography afforded 2h free base (0.145 g, 25%) as a colorless oil. 1H-NMR
(CD3OD): δ 7.58 (d, J = 8.0 Hz, 2H), 7.45 (d, J = 8.0 Hz, 2H), 6.61 (d, J = 8.4 Hz, 1H), 6.56 (d, J = 8.4 Hz,
1H), 4.77 (s, 1H), 3.34–3.32 (m, 1H), 2.97 (d, J = 18.4 Hz, 1H), 2.93–2.72 (m, 5H), 2.60 (dt, J = 12.8 Hz,
3.4 Hz, 1H), 2.54 (td, J = 14.0 Hz, 4.8 Hz, 1H), 2.38 (dd, J = 18.6 Hz, 5.8 Hz, 1H), 2.29 (dt, J = 14.0 Hz,
3.0 Hz, 1H), 2.23 (td, J = 12.2 Hz, 3.4 Hz, 1H), 2.12 (td, J = 12.2 Hz, 4.2 Hz, 1H), 1.88–1.82 (m, 1H), 1.69
(d, J = 11.6 Hz, 1H), 1.15 (ddd, J = 27.2 Hz, 13.2 Hz, 2.4 Hz, 1H); 13C-NMR (CD3OD): δ 210.4, 144.1,
139.2, 129.0, 128.5, 128.1, 127.8, 127.5, 127.0, 124.9, 124.8(2), 124.7(2), 119.6, 117.3, 91.0, 57.3, 56.0, 47.2,
44.8, 41.6, 39.4, 34.7, 33.4, 25.3, 20.5; HRMS (TOF MS ES+) calcd for C25H25F3NO3 [M + H]+ 444.1787,
found 444.1788. An HCl salt was prepared by dissolving 2h free base in hot i-PrOH (5.0 mL) followed
by the addition of concentrated aq HCl (0.10 mL, 3 equiv) and cooling to 5 ◦C. The crystals were
filtered and air-dried to give 2h as its HCl salt. Anal. Calcd for C25H24F3NO3·HCl·0.5H2O·0.5C3H8O
(2h·HCl·0.5H2O·0.5C3H8O): C, 61.31; H, 5.73; N, 2.60; found: C, 61.33; H, 5.83; N, 2.70%. [α]20D − 122.0
(c 0.4, MeOH, HCl·0.5H2O·0.5i-PrOH).
(7aR,12bS)-3-(4-Chlorophenethyl)-9-hydroxy-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]-
isoquinolin-7(7aH)-one (2i): See the General Procedure in 3.2.
(4R,7aR,12bS)-3-(4-Bromophenethyl)-9-hydroxy-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]-
isoquinolin-7(7aH)-one oxalate (2j): The general procedure with S10 (0.3 g, 1.11 mmol), 4-bromophenethyl
bromide (0.586 g, 2.22 mmol), NaHCO3 (0.50 g, 5.95 mmol), and DMF (10 mL) at room temperature.
The reaction was heated to 60 ◦C for 20 h cooled to room temperature, and filtered through a pad
of Celite. The DMF was removed via azeotrope with toluene (3 × 20 mL), then purification by SiO2
column chromatography with 10% NH4OH in MeOH/CHCl3 (0%→ 5% of 10% NH4OH) gave the base
2j ree base (0.212 g isolated, 41% yield) as a light brown oil. An oxalate salt was prepared by dissolving
2j in a minimal amount of hot i-PrOH followed by addition of a concentrated solution of oxalic acid in
isopropanol. Cooling at 5 ◦C overnight gave 2j·oxalate as a precipitate (0.131 g, 44/%), mp 201−204 ◦C.
1H-NMR (CD3OD): δ 7.39 (d, J = 8.1 Hz, 2H), 7.07 (d, J = 8.1 Hz, 2H), 6.71 (d, J = 8.1 Hz, 1H), 6.58
(d, J = 8.1 Hz, 1H), 4.65 (s, 1H), 3.34 (d, J = 0.4 Hz, 1H), 2.96 (t, J = 15.8 Hz, 1H), 2.78–2.69 (m, 5H),
2.65–2.61 (m, 1H), 2.38–2.32 (m, 3H), 2.27–2.21 (m, 1H), 2.16–2.07 (m, 1H), 1.84–1.76 (m, 2H), 1.27–1.18
(m, 2H).13C-NMR (CD3OD): δ 209.12, 144.04, 139.08, 138.89, 131.39, 130.47, 126.78, 125.05, 120.26,
119.89, 118.00, 91.35, 57.67, 56.64, 47.40, 45.03, 42.11, 40.13, 35.16, 33.63, 25.41, 20.98; HRMS (TOF MS
ES+) C24H24BrNO3 (M+H+) 454.1018, found 454.1021. Anal. Calcd for C24H24BrNO3·C2H2O4·2H2O
(2j·C2H2O4·2H2O) C, 54.31%; H, 5.15%; N, 2.44%; found: C, 54.09%; H, 5.04%; N, 2.71%. [α]20D −87.0 (c
1.2, MeOH, C24H24BrNO3·C2H2O4·2H2O).
(7aR,12bS)-3-(2,6-Dichlorophenethyl)-9-hydroxy-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]
isoquinolin-7(7aH)-one (2k): The general procedure with S10 (0.56 g, 2 mmol), 2,6-dichlorophenethyl
bromide (1.0 g, 4 mmol), NaHCO3 (0.70 g, 8.3 mmol), and DMF (10 mL). Purification by column
chromatography afforded 2k free base (0.012 g, 0.02 mmol, 2%) as a yellow oil. The oil was taken up in
acetone (2 mL) and oxalic acid (0.002 g) added to give pure 2k·oxalate (0.014 g) as a white powder.
1H-NMR (DMSO-d6): δ 7.49 (d, J = 8.0 Hz, 2H), 7.32 (t, J = 8.0 Hz, 1H), 6.58 (q, J = 7.5 Hz, 2H), 4.91
(s, 1H), 3.72–3.70 (m, 1H), 3.24–3.13 (m, 2H), 3.10–2.93 (m, 3H), 2.91–2.81 (m, 1H), 2.76–2.66 (m, 1H),
2.63–2.54 (m, 2H), 2.39–2.32 (m, 1H), 2.20–2.16 (m, 2H), 1.86–1.83 (m, 1H), 1.65–1.62 (m, 1H), 1.06–0.95
(m, 1H); 13C-NMR (DMSO-d6): δ 208.6, 163.2, 144.4, 140.0, 135.2, 129.9, 129.0, 120.0, 117.7, 90.4, 57.9,
46.2, 31.1, 25.0; m.p. 204-206 ◦C (decomp); HRMS (ESI): Calcd for C26H26Cl2NO7 [M + H]+ 444.1133,
found: 444.1129; Anal. Calcd for C26H25Cl2NO7 ·2.25 H2O:C, 54.32; H, 5.17; N, 2.44; found: C, 54.22; H,
4.86; N, 2.59.
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3.3. In Vitro Pharmacology.
3.3.1. Opioid Receptor Binding Affinity
Frozen whole rat brains excluding cerebellum were thawed on ice, homogenized in 50 mM
Tris HCl, pH 7.5 using a Polytron (Brinkman Instruments, Westbury, NY, USA), setting 6 for 20 s),
and centrifuged at 30,000× g for 10 min at 4 ◦C. The supernatant was discarded and the pellet was
re-suspended in fresh buffer and spun at 30,000× g for 10 min. The supernatant was discarded and
the pellet was re-suspended to give 100 mg/mL original wet weight. Ligand binding experiments
were conducted in polypropylene assay tubes containing 0.5 mL Tris HCl buffer for 60 min at room
temperature. [3H]DADLE (final concentration 1 nM, PolyPeptide Laboratories, San Diego, CA, USA),
[3H]DAMGO (final concentration 1 nM, PolyPeptide Laboratories, San Diego, CA, USA) or [3H]U69,593
(final concentration 1 nM, Perkin Elmer Life Sciences, Waltham, MA, USA) were used to determine
binding at δ-, µ- and κ-opioid receptor sites, respectively. Unlabeled DAMGO (final concentration,
30 nM) was added to the delta assay tubes to block µ-receptor binding. All assay tubes contained
100 µL homogenate suspension. Nonspecific binding was determined in all assays using 0.01 mM
naloxone. Incubations were terminated by rapid filtration through Whatman GF/B filters, presoaked in
0.1% polyethyleneimine, using a Brandel R48 filtering manifold (Brandel Instruments Gaithersburg,
Maryland). The filters were washed twice with 5 mL cold buffer and transferred to scintillation vials.
Cytoscint (MP BioMedicals, Santa Ana, CA, USA) 3.0 mL) was added and the vials were counted the
next day using a Perkin Elmer TriCarb liquid scintillation counter. Data were analyzed with GraphPad
Prism software (GraphPad Inc., San Diego, CA, USA).
3.3.2. Stimulation of [35S]GTPγS Binding
All tissue culture reagents were purchased from Gibco Life Sciences (Grand Island, NY, USA).
C6-rat glioma cells stably transfected with a rat MOR or rat DOR [38] and Chinese hamster ovary
(CHO) cells stably expressing a human KOR [39] were used for all in vitro assays. Cells were grown to
confluence at 37 ◦C in 5% CO2 in Dulbecco’s Modified Eagle Medium (DMEM) containing 10% fetal
bovine serum and 5% penicillin/ streptomycin. Membranes were prepared by washing confluent cells
three times with ice-cold phosphate buffered saline (0.9% NaCl, 0.61 mM Na2HPO4, 0.38 mM KH2PO4,
pH 7.4). Cells were detached from the plates by incubation in warm harvesting buffer (20 mM HEPES,
150 mM NaCl, 0.68 mM EDTA, pH 7.4) and pelleted by centrifugation at 1600 rpm for 3 min. The cell
pellet was suspended in ice-cold 50 mM Tris-HCl buffer, pH 7.4, and homogenized with a Tissue Tearor
(Biospec Products, Inc., Bartlesville, OK, USA) for 20 s. The homogenate was centrifuged at 15,000 rpm
for 20 min at 4 ◦C. The pellet was re-homogenized in 50 mM Tris-HCl with a Tissue Tearor for 10 s,
followed by re-centrifugation. The final pellet was re-suspended in 50 mM Tris-HCl and frozen in
aliquots at 80 ◦C. Protein concentration was determined via a BCA protein assay (Thermo Scientific
Pierce, Waltham, MA, USA) using bovine serum albumin as the standard.
Agonist stimulation of [35S]guanosine 5′-O-[γ-thio]triphosphate ([35S]GTPγS, 1250 Ci, 46.2 TBq/mmol)
binding to G-protein was measured as described previously [40]. Briefly, membranes (10−20 µg
of protein/tube) were incubated 1 h at 25 ◦C in GTPγS buffer (50 mM Tris-HCl, 100 mM NaCl,
5 mM MgCl2, pH 7.4) containing 0.1 nM [35S]GTPγS, 30 µM guanosine diphosphate (GDP),
and varying concentrations of test compound. G-Protein activation following receptor stimulation of
[35S]GTPγS (% stimulation) with test compound was compared with 10 µM of the standard compounds
[D-Ala2,N-MePhe4,Gly-ol]- enkephalin (DAMGO) at MOR, D-Pen2,5-enkephalin (DPDPE) at DOR,
or U69,593 at KOR. The reaction was terminated by vacuum filtration of GF/C filters that were washed
10 times with GTPγS buffer. Bound radioactivity on dried filters was determined by liquid scintillation
counting, after saturation with EcoLume liquid scintillation cocktail, in a Wallac 1450 MicroBeta
(PerkinElmer, Waltham, MA, USA). The results are presented as the mean ± standard error (SEM) from
at least three separate assays performed in duplicate; potency (EC50 (nM)) and % stimulation were
determined using nonlinear regression analysis with GraphPad Prism.
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3.3.3. Forskolin-Induced cAMP Accumulation Assays
Cell Lines and Cell Culture
HitHunter Chinese hamster ovary cells (CHO-K1) that express human µ-opioid receptor
(OPRM1), human κ-opioid receptor (OPRMK1), and human δ-receptor (OPRMD1) were used for the
forskolin-induced cAMP accumulation assay. PathHunter CHO cells expressing human µ-opioid
receptor β-arrestin-2 EFC cells were used for the β-arrestin-2 EFC recruitment assay. Both cell lines were
purchased from Eurofins DiscoverX (Fremont, CA, USA). Cell culture was performed as previously
described [41].
Assays
These were performed as previously described using HitHunter CHO-K1 cells expressing either
human OPRM1, OPRK1, or OPRMD1 cells. Briefly, cells were dissociated from culture plates and
plated at 10,000 cells/well in a 384-well tissue culture plate and incubated overnight at 37 ◦C in 5% CO2.
Stock solutions of compound were made in 100% DMSO at a 5 mM concentration. A serial dilution of
10 concentrations was made using 100% DMSO, creating 100× solutions of the compound for treatment.
The 100× solutions were then diluted to 5× solutions using assay buffer consisting of Hank’s Buffered
Salt Solution, HEPES, and forskolin. The HitHunter cAMP Assay for Small Molecules by DiscoverX was
then used according to manufacturer’s directions, utilizing the 5× solutions containing the compound
studied. Cells were incubated with compound for 30 min at a 1× concentration. The following day,
the Cytation 5 plate reader and Gen5 Software were used to quantify luminescence (BioTek, Winooski,
VT, USA) [41].
3.3.4. β-Arrestin-2 EFC Recruitment Assay
Assays were performed as previously described [41] using PathHunter human µ-opioid receptor
β-arrestin-2 EFC cells. Briefly, cells were dissociated from culture plates and plated at 5000 cells/well in a
384-well tissue culture plate and incubated overnight at 37 ◦C in 5% CO2. Stock solutions of compound
were made in 100% DMSO for a final concentration of 5 mM. A serial dilution of 11 concentrations was
made using 100% DMSO to create 100× solutions of the compound. Assay buffer containing Hank’s
Buffered Salt Solution and HEPES was used to dilute the 100× solutions to 5× solutions. The DiscoverX
PathHunter assay was used according to manufacturer’s instructions. Cells were treated with the
compounds for a final 1× concentration for 90 min. at 37 ◦C and 5% CO2. Reagents from the assay kit
were used accordingly and the cell culture plate was protected from light for 1 h. Cytation 5 plate
reader and Gen5 Software were used to quantify luminescence (BioTek).
3.3.5. Data Analysis
Data were analyzed as previously described [42] using GraphPad Prism 6.0 software (GraphPad,
San Diego, CA, USA different address given before). Briefly, sigmoidal dose-response curves in the
forskolin-induced cAMP accumulation assay and the β-arrestin2 EFC recruitment assay were generated
using nonlinear regression analysis. Compounds were evaluated in triplicate in individual experiments
with n ≥ 2. All values in the cAMP accumulation assay and β-arrestin2 recruitment assay are reported
as the mean ± SEM. Bias factors were calculated using Equation (1) shown below.
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3.4. In Vivo Pharmacolog
3.4.1. Measurement of Respiration Rate and Arterial Oxygen Saturation in Mice
Male Swiss Webster mice (Taconic Biosciences, Germantown, NY, USA) weighing 30–35 g were
used. Mice were housed in a temperature- and humidity-controlled environment with a 12-h light-dark
cycle in the Temple University Animal Care Facility. They were supplied with food and water ad
libitum. Before any procedure was applied, the mice were acclimated for 1 week in the animal facility.
Behavioral testing was performed between 11:00 a.m. and 5:00 p.m. On the day of the experiment,
mice were brought to the room and acclimated for 45–60 min in the observation boxes All animal care
and experimental procedures were approved by the Institutional Animal Care and Use Committee of
Temple University (Protocol #4793 Respiration Measurement in Mice; Approval Date: 1 June 2018),
and conducted according to the NIH Guide for the Care and Use of Laboratory Animals.
Respiration and oxygen saturation (SpO2) were measured using MouseOx Plus Rat and Mouse
Pulse Oximeter (Starr Life Sciences Corp, Oakmont, PA, USA) in conscious, freely moving animals.
Animals were exposed to 4% isoflurane for 30 s to connect throat collar sensor and to inject (s.c.) either
saline, morphine 10 mg/kg, or 2i (0.01–0.1 mg/kg, n = 6–8). Mice were then placed into observation
boxes and recording was started 5 min later to eliminate any anesthesia effect. Respiration and
SpO2 were recorded every second and averaged over 1-min periods for 40 min. Morphine, 10 mg/kg,
was used as a positive control [43].
3.4.2. Statistical Analysis
Area under the curve (AUC) was calculated from 6 min to 45 min and analyzed using one-way
analysis of variance (ANOVA) followed by Dunnett’s multiple comparison test. Data are expressed
as mean ± standard error of the mean (S.E.M.), and p < 0.05 was accepted as statistically significant.
GraphPad Prism, version 7, was used for data analysis.
3.5. Warm-Water Squirrel Tail-Withdrawal and Operant Responding
Male squirrel monkeys (Saimiri sciureus) were housed in a climate-controlled vivarium with a
12-h light/dark cycle (7 AM–7 PM) in the McLean Hospital Animal Care Facility (licensed by the U.S.
Department of Agriculture and compliant with guidelines provided by the Committee on Care and
Use of Laboratory Animals of the Institute of Laboratory Animals Resources, Commission on Life
Sciences, National Research Council; 2011). Tail withdrawal latencies and food-maintained behavior
were assessed as described previously [44]. Briefly, monkeys were seated in customized Plexiglas
chairs that allowed their tails to hang freely behind the chair and were equipped with colored stimulus
lights, a response lever, and a receptacle into which 0.15 mL of 30% sweetened condensed milk could
be delivered. Animals were trained to respond under a fixed-ratio 10-response (FR10) schedule of
food reinforcement in the presence of red stimulus lights. Completion of 10 responses in less than
20 s resulted in milk delivery, and initiated a timeout (TO) period of 30 s during which all stimulus
lights remained off. Failure to complete 10 responses within 20 s initiated the 30 s TO. Tail withdrawal
latencies were measured during the 30 s TO periods by immersing the subject’s tail in water held
at 35 ◦C, 50 ◦C, 52 ◦C, or 55 ◦C (each temperature of water was presented in a randomized order).
Experimental sessions were 4 or 5 sequential cycles, each composed of a 10 min TO during which
no lights were on and responding had no programmed consequences followed by a 5 min response
component during which the FR10 schedule of food reinforcement and interspersed determinations of
tail withdrawal latencies was in effect. Cumulative doses of 2i or morphine were administered shortly
after the onset of the 10 min TO.
3.6. Squirrel Monkey Ventilation
Male squirrel monkeys were acclimated to a customized round acrylic chamber (13.75′′ day × 15′′ h)
that served as a whole-body plethysmograph (EMKA Technologies, Montreal, PQ, Canada). Gas (either
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air or a 5% CO2 in air mixture) was introduced to and extracted from the chamber at a constant flow
rate of 5 L/min. Experimental sessions consisted of 4–6 consecutive 30 min cycles, each comprising a
15 min exposure to air followed by a 15 min exposure to 5% CO2. Drug effects were determined using
cumulative dosing procedures, and injections were administered following each exposure to 5% CO2.
Respiratory rate and tidal volume (mL/breath) were recorded over 1 min periods and were multiplied
to provide minute volumes. Data from the last three minutes of each exposure to air or CO2 were
averaged and used for analysis of drug effects on ventilation.
4. Computational Methods
All the ligands considered in this study and their conformers (see Table S1 and Figure S2A in SI)
in their protonated form were geometry optimized via quantum chemical (QM) calculations at the
B3LYP/6-31G* level in the gaseous phase as implemented in Gaussian 09 software [45]. The atomic
polar tensor derived charges from these calculations were used to assign a partial charge on each atom
for the ligands. All other parameters were determined by chemical analogy with the topology and the
parameters files of the all-atom CHARMM force field (version c42b2) [46]. The structures of the inactive
forms of MOR (PDB # 4DKL) and DOR (4EJ4) were taken as the starting configurations. After removing
the cocrystallized ligands and crystal water/ions, the intracellular loop (ICL3) connecting TM5 and TM6
was first modeled in each receptor using MM (ab initio) methods [8,47,48]. The modeled receptors were
then embedded in a membrane composed of zwitterionic 1-palmitoyl-2-oleoyl-phosphatidylcholine
lipid molecules with initial concentrations of Na+, K+, and Cl– ions in the extracellular (EC) and
intracellular (IC) regions. All the amino acids were assumed to be neutral at physiological pH
except Asp–, Glu–, Lys+ and Arg+; additional ions were used to neutralize the systems. The initial
orientation and relative position of the receptor with respect to the membrane were obtained from
the OPM database [49]. The receptor and the membrane were then solvated in TIP3P water, and a
single Na+ ion was introduced in the binding pocket and coordinated as in the DOR (4N6H) [50].
The system was then energy minimized and thermally equilibrated according to the following protocol:
first, the conformation of the receptor and Na+ were kept fixed, and the membrane and water were
gradually heated to the target temperature (37 ◦C) at constant pressure (1 atm); the system was then
equilibrated for 5 ns; the constraints on the side chains and ion were then removed, and the system
equilibrated for another 5 ns; finally, all the constraints were removed, and the system equilibrated
for another 5 ns. Throughout the entire equilibration process, the ion remained coordinated with the
anchoring aspartic acid D147 (MOR) and D128 (DOR) (sequence numbering follows the corresponding
crystal structures). A conformation (snapshot) of each system at the end of the final equilibration
phase was used to dock the ligands. These are the basal conformations that all the ligands “see”
before entering the binding pocket, and were used for all the comparative analyses, regardless of
the experimentally determined activity or pharmacological outcome. After removing the Na+ ion,
the ligands (and their conformers) were rigidly docked into the binding pocket based on two criteria:
the close contact between the charged amine and the anchoring Asp– and the binding mode of the
antagonists β-FNA and naltrindole co-crystallized with the MOR and the DOR, respectively. Several
conformers (cf. Figure S2) could be eliminated by steric considerations alone. Others (especially those
involving rotations of φ1; cf. Figure S2) could still dock without apparent steric clashes upon small
relaxations of the pocket side chains, but they tended to lose the critical interaction with Asp– in the
course of equilibration or early production; when this occurred in repeated simulations, the conformer
was discarded. Overall, between one and four stable conformers were left for each ligand (see Table S2).
The three-stage equilibration protocol described above for Na+ was repeated for each ligand/conformer
after docking. Steric relaxation of the ligand and residues in the pocket set in during the early stages
of equilibration. Five independent 50 ns molecular dynamics simulations were conducted for each
system at 37 ◦C and 1 atm, using periodic boundary conditions and particle mesh Ewald summations.
This simulation time was sufficient to ensure convergence and statistical analysis of the quantities
of interest (hydrophobic contacts, H-bonds, electrostatic interactions), which were computed after
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structural relaxation set in (estimated from Cα-RMSD vs. time), typically during the last half of the
dynamic trajectory (production run). The results combine data from all the independent simulations
for each ligand conformer/OR.
5. Conclusions
We hypothesized that substituents at the tail end of the body of a large molecule might modify the
in vitro activity and/or potency of the compound and possibly modify a G-protein biased compound
that acted primarily through MOR to a bifunctional ligand. We found that a substituent, a chlorine
atom, modified the activity of N-phenethylnorhydromorphone (S11), a potent full agonist with a
DOR-MOR δ/µ potency ratio of 38.5, to a compound with a δ/µ potency ratio of 1.2, N-p-chloro
phenethylnorhydromorphone (2i). It exhibited potent partial MOR agonist and potent full DOR
agonist activity. In fact, the introduction of a p-Cl substituent (2i) in the N-phenethyl moiety did not
particularly reduce the MOR potency of S11 but instead increased its DOR potency; it induced a change
from a molecule that acted primarily as a MOR ligand to a bifunctional compound with the ability to
interact potently with MOR and DOR. This change was due to a simple substituent at the tail end of
the compound. Molecular modeling and simulations found that the substituent on the aromatic ring of
the N-phenethyl moiety is located in an area where relatively small changes in the N-phenylethyl ring
via substitution perturb residues located in quite different regions of the opioid receptors and engage
different TMHs. In theory, the combination of MOR and DOR properties found in 2i might have made
the compound less likely than other potent analgesics to cause respiratory depression [17]. Indeed,
that was found to be the case in mice using normal air, where a clear difference was found between the
effects of 2i and morphine on respiration. Both 2i and morphine are partial agonists; if the lack of effect
on respiration was due to the partial agonist character of 2i, the same effect would be expected with
morphine. The ability of 2i to recruit β-arrestin2 at least as well as morphine (Table 2) would predict
that it should exhibit all of the side-effects known to occur with morphine. The inability of 2i to depress
respiration in mice might indicate that the recruitment of β-arrestin2 may not be the cause of all of the
side-effects seen with opioids [4]. However, with squirrel monkeys under more stringent conditions,
in an assay using 5% CO2 mixed in air, 2i was found to be as effective as morphine in depressing
respiration. Further work is necessary to determine whether 2i will produce the gastrointestinal effects,
tolerance, and dependence that occur with other G-protein biased opioids.
6. Patents
K. C. Rice, A. E. Jacobson, F. Li, E. Gutman, E. W. Bow: Biased Potent Opioid-Like Agonists as
Improved Medications to Treat Chronic and Acute Pain and Methods of Using the Same. International
Application PCT/US19/22701, 18 March 2019 (PCT Application Serial No.: PCT/US2019/022701, filed 18
March 2019). Patent No. WO 2019182950.
Supplementary Materials: 1H and 13C-NMR spectra of novel compounds, molecular modeling, and dynamics
simulations, and Scheme S1, the Synthesis of hydromorphone (S5). N-norhydromorphone (S10) and N-phenethy
lnorhydromorphone (S11).
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